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ORIGINAL PUBLICATIONS 
 
This dissertation is based on the following publications as well as previously unpublished data on 
metastatic uveal melanoma. The original publications in the text will be referred to by their Roman 
numerals I-IV: 
 
I Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular loops and networks as 
prognostic indicators in choroidal and ciliary body melanomas. J. Natl. Cancer Inst. 
1999;91:359-367. 
 
II Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Microvascular density in predicting 
survival of patients with choroidal and ciliary body melanomas. Invest. Ophthalmol. Vis. 
Sci. 1999;40:2471-80. 
 
III Mäkitie T, Summanen P, Tarkkanen A, Kivelä T. Tumor-infiltrating macrophages (CD68+ 
cells) and prognosis in malignant uveal melanoma. Invest. Ophthalmol. Vis. Sci. 
2001;42:1414-1421. 
 
IV Mäkitie T, Carpén O, Vaheri A, Kivelä T. Ezrin as a prognostic indicator and its 
relationship to tumor characteristics in malignant uveal melanoma. Invest. Ophthalmol. 
Vis. Sci, Under revision. 
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ABBREVIATIONS 
 
ABC  Avidin-biotinylated peroxidase complex 
AFIP The Armed Forces Institute of Pathology  
BMDP Statistical software package 
BSA Bovine serum albumin 
CD Cluster of differentiation 
CI Confidence interval 
CK Cytokeratin 
c-met The receptor of hepatocyte growth factor 
COMS The Collaborative Ocular Melanoma Study  
DAB Diaminobenzidine 
DNA Deoxyribonucleic acid 
ECM Extracellular matrix 
EGFR Epidermal growth factor receptor 
EMA Epithelial membrane antigen 
ER Estrogen receptor 
FVIII-RAg Factor VIII-related antigen 
Gy Gray, a unit of radiation 
HGF Hepatocyte growth factor 
HLA Human leukocyte-associated 
HR Hazard ratio 
ICAM Intercellular cell adhesion molecule  
IHC Immunohistochemistry 
Ki-67 A proliferation-associated antigen 
LBD Largest basal tumor diameter 
mAb Monoclonal antibody 
KDR Receptor of vascular endothelial growth factor 
MMP Matrix metalloproteinase 
MVD  Microvascular density 
NCAM Neural cell adhesion molecule 
p Short arm of a chromosome 
PAS  Periodic acid-Schiff 
PBS Phosphate-buffered saline 
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PC-10 A proliferation-associated antigen 
q Long arm of a chromosome 
RD Retinal detachment 
SE Standard error 
SPSS Statistical software package 
TNM System for classifying the extent of tumor spread 
UEA-I Ulex europaeus agglutinin I 
UV Ultraviolet 
v/v Volume/volume 
w/v Weight/volume 
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INTRODUCTION 
 
Cancer and blindness are among the most feared destinies.1,2 These two miseries are combined in 
intraocular tumor. The most common intraocular tumors are benign melanocytic uveal nevi and 
secondary metastatic tumors.3 Malignant melanoma of the uvea is, however, the most common 
primary malignant intraocular tumor in adults.4,5  
 
Uveal melanoma differs markedly from cutaneous melanoma, although both originate from 
melanocytes.3,6 Unlike in cutaneous melanoma, UV light and hereditary predisposition have little or no 
effect on initiation of uveal melanoma.5-8 Intraocular melanoma disseminates hematogeneously, 
because interior of the eye lacks lymphatics, and it has a great propensity to develop distant metastases, 
in particular in the liver, whereas cutaneous melanoma tends to disseminate in regional lymph 
nodes.2,9-12 Recent studies have revealed substantial cytogenetic and molecular differences between 
these tumors, which probably explain their divergent biological behaviour.13-15   
 
The uvea consists of three elements: the iris, ciliary body and choroid (Fig. 1).3 Melanomas that arise 
from the iris differ markedly from those of the choroid and ciliary body. Due to their anatomic location 
that favours early diagnosis and, perhaps, their relatively benign cellular composition, deaths from iris 
melanoma are markedly less common than deaths from choroidal and ciliary body melanoma.3,16-18 
Consequently, iris melanomas are not included in the present study, and uveal melanoma in the present 
thesis refers exclusively to choroidal and ciliary body melanoma.  
 
Malignant uveal melanomas were treated for decades by a prompt removal the eye; by 1970’s 
conservative treatment methods such as plaque brachytherapy, charged particle irradiation and 
transscleral local resection came into daily clinical practice.19,20 Since no convincing difference in 
survival has been detected between radical surgery of the eye and eye conserving therapies, functional, 
psychological, and cosmetic advantages of saving the eye have increased the popularity of conservative 
methods.20-27 Even though new treatment options have shown their safety as compared to the 
traditional enucleation, no significant improvement has taken place in the outcome of patients with 
uveal melanoma.22,23 Obviously in most cases, intraocular melanoma has already disseminated at the 
time when treatment of the primary tumor is given; the choice between radical and conservative 
therapy does not necessarily have a great impact on survival.23,28 Manifest disseminated uveal 
melanoma is still an unbeatable challenge for oncologists; the median survival after metastatic disease 
is only from a few months to one year.29-31  
 Introduction 
________________________________________________________________________________ 
 11   
 
In order to improve the survival of uveal melanoma patients, an effective and safe adjuvant therapy is 
needed, since high-risk and even many low-risk patients have micrometastases at the time of diagnosis 
of the primary tumor.28,29,32 As our understanding of the metastatic process is far from complete, 
prognostic studies on uveal melanoma are warranted to recognise patients with high, moderate, or low 
risk for metastasis. Because little histopathological material is currently obtained as compared with the 
earlier era of routine enucleation, evaluation of prognosis at the time of treatment of the primary tumor 
has, in fact, become much more challenging after development of eye-conserving treatments.         
 
Figure 1. Schematic drawing of the eye. The equator determines tumor location to anterior and 
posterior 
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REVIEW OF LITERATURE 
 
1. MALIGNANT UVEAL MELANOMA 
 
1.1 Epidemiology 
 
Uveal melanoma is the most common malignant primary tumor of the eye in Caucasian adults.5 The 
annual incidence of malignant uveal melanoma ranges from 6 to 8 new cases per million Caucasians, 
but its incidence is 15 to 50 times lower in Africans and Orientals.5 Retinoblastoma exceeds uveal 
melanoma in frequency among non-Caucasians.33 In a large epidemiological study conducted in 
Finland in 1977, Raivio reported an annual incidence of 5 per million persons, which means 
approximately 25 new melanoma patients per year in the 5 million population of Finland.34 During 
recent years the incidence of uveal melanoma has been somewhat higher, ranging from 30 to 40 
intraocular melanomas per year in Finland. This variation is most likely explained by incomplete early 
data collections of the Finnish Cancer Registry, founded in 1952. In two other Scandinavian 
populations, the Danish and the Swedish, the incidence is 7.1 and 7.2 per million inhabitants, 
respectively.35,36 In contrast to the strikingly increasing incidence of cutaneous melanoma, the 
frequency of uveal melanoma has not changed during the last two decades.5  
 
The incidence of uveal melanoma depends on age: uveal melanoma is very rare in childhood, but its 
incidence increases in older age groups achieving a peak in late middle age (50-60y).5 Persons with 
lightly pigmented skin, hair, and irises, not uncommon features among the Scandinavians and the 
Finnish in particular, are at slightly increased risk of developing uveal melanoma.35,37,38 A slight 
predominance of male gender is evident from large series of uveal melanoma, but the reason for the 
male predominance is unknown.5 
 
1.2 Aetiology and Predisposition 
 
Neuroectodermally derived melanocytes of the choroid, ciliary body and iris give rise to uveal 
melanoma.3 The highly vascularised choroid is the largest part of the uveal tract and the most common 
site for intraocular melanoma.39 Of uveal melanomas, 80% grow in the choroid, 15% involve both the 
choroid and the ciliary body, and 5% are confined to the ciliary body, iris, or both.39 Diffuse uveal 
melanoma has an uncommon growth pattern, representing approximately 5% of posterior uveal 
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melanomas. It is named for its flat shape and small height and it may affect large areas of the choroid.40 
Variants of diffuse uveal melanoma are a ring melanoma that grows circumferentially in the ciliary 
body and a retinoinvasive melanoma that invades extensively retina and extends to optic nerve.41,42 
Rarely cutaneous melanoma can metastasize intraocularly.43 These metastatic melanomas often grow 
in the retina and vitreous body that are rarely involved by uveal melanomas.42,43 
 
In addition to age and race, one of the best-documented predisposing lesions is the relatively common 
choroidal nevus; 3-20% of the population has at least one choroidal nevus.3  However, only a small 
minority of nevi (1 in 15000) transforms to malignant melanoma per year.3 In contrast to skin 
melanoma, ultraviolet exposure does not correlate with development of uveal melanoma, but 
contradictory reports also exist.5,37  
 
Congenitally increased number of melanocytes, known as congenital ocular melanocytosis and 
congenital oculodermal melanocytosis (the nevus of Ota) are more common among patients with uveal 
melanoma than in the general population.5 The lifetime risk for developing uveal melanoma is 1:400 
for a patient with ocular melanocytosis.44 The dysplastic nevus syndrome is also associated with an 
increased risk of uveal melanoma.45,46  
 
Hormonal factors, like childbearing history and hormonal therapy have been studied as etiological 
factors, but no convincing connection between hormonal factors and uveal melanoma has been 
established.47,48  
 
Even though knowledge of cancer genetics has markedly increased, the genes involved in the 
development and progression of uveal melanoma are not yet known. Some frequent chromosomal 
changes, such as monosomy of chromosome 3 and structural alterations of chromosomes 6 and 8 are 
distinctly connected with uveal melanoma.49-51 In spite of occasional uveal melanomas in first-degree 
relatives, no convincing evidence for familial inheritance exists.8,52 
 
1.3 Diagnosis 
 
Most patients with uveal melanoma have symptoms of blurred vision, visual field loss, photopsia, 
floaters, and rarely, pain before diagnosis; 10-30% of uveal melanomas are diagnosed during routine 
ophthalmologic examination in the absence of any preceding symptoms.53-55 Indirect ophthalmoscopy 
is widely used in making the diagnosis of choroidal melanoma.41 Of medium-sized and large uveal 
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melanoma, up to 99% are diagnosed correctly by clinical methods.56 Clinical diagnosis may be 
difficult, however, when differentiating small melanoma from nevi.20,41 Documented growth is often 
needed to confirm the diagnosis of small melanomas, but also nevi may slowly grow in follow-up.20,41 
Exudative retinal detachment is very frequently associated with choroidal melanoma, which may help 
in diagnosis of a small melanoma, but it may also obscure an underlying larger tumor and delay 
diagnosis.57 
 
Uveal melanoma may break two layers: the overlying Bruch’s membrane and the underlying sclera.3 
Having broken the Bruch’s membrane, choroidal melanoma has an access to the subretinal space, 
immediately achieving a shape of “collar button” or “mushroom”, which are highly characteristic of, 
even pathognomic of choroidal melanoma (Fig. 2).3 It may then also invade the overlying retina and 
extend to the vitreous cavity. The outermost layer of the eye, sclera, can resist local invasion to orbit 
for years, except close to the optic disc. 
 
Figure 2. Mushroom-shaped choroidal melanoma that has ruptured Bruch’s membrane. Patient died 
of hepatic metastases three years after enucleation 
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Transillumination of the eye helps to estimate the anterior margins of the tumor in lightly pigmented 
individuals. Development of B-scan ultrasonography has greatly helped ophthalmologists in making 
the diagnosis of choroidal tumors, and thus, the rate of misdiagnosis has markedly decreased during 
last decades.41,56 High frequency ultrasonography helps in diagnosis of ciliary body tumors.58 
Computed tomography and magnetic resonance imaging are optional methods.41 The cellular 
composition of the intraocular tumor can be assessed by fine-needle aspiration biopsy performed either 
via a transscleral or a transvitreal route, but this method has been so far limited to patients whose 
clinical diagnosis is in doubt and to experimental use.59,60 “Double circulation” consisting of choroidal 
and tumor vessels that are leaky in late phases of a fluorescein fundus angiography is characteristic of 
uveal melanoma, but angiography does not differentiate a malignant lesion from a benign one 
reliably.41 
 
The diagnosis of metastatic disease is conventionally based on liver function tests and chest x-ray 
examination.29,30 However, screening for metastatic uveal melanoma by abdominal ultrasonography 
and computed tomography were found to be more sensitive methods for detecting metastatic disease.12 
Liver function tests, nevertheless, provide confirmatory evidence.12 
 
1.4 Treatment               
 
Enucleation was the standard and only treatment of uveal melanoma for decades until eye-conserving 
methods developed in the 1950´s came to clinical use in late 1960´s.61 Enucleation is still an effective 
and acceptable treatment modality, especially for large melanomas and under circumstances in which 
the availability of conservative methods is limited, like in developing countries.41 Enucleation has a 
excellent local tumor control, approaching to 100% if no extraocular extension is present at the time of 
surgery.62 The American Collaborative Ocular Melanoma Study  (COMS) was initiated in 1986 to 
resolve whether or not any difference in survival between enucleation and radiotherapy exists.63 A 
large number of patients with medium-sized melanoma have been randomised either to enucleation or 
iodine plaque radiotherapy, and comparative survival statistics will be published by year 2003. 
Retrospective studies on effectiveness and safety of radiotherapy as compared to enucleation have 
shown that a significant difference between these two treatment methods is unlikely, which have 
already declined enucleation rates especially in European and American ophthalmic centers.22-26,41 
 
Radiotherapy given either with episcleral radioactive plaques (cobalt60, iodine125, ruthenium106, 
iridium192 or palladium103) or with accelerated protons or helium ions often saves some functional 
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vision in the eye with uveal melanoma particularly when the tumor is small.19,64-66 Uveal melanoma is, 
however, resistant to markedly higher doses of irradiation than the retina and the optic nerve, which 
increases the risk for visual impairment due to radiation retinopathy and optic neuropathy.19,65-67 
Recurrences of uveal melanoma after radiotherapy range from 5 to 10% within 5 years and local 
recurrences may indicate even a 5-fold risk for metastatic disease.68,69 It also remains a possibility that 
tumors that recur were initially more malignant. Low-dose (4-8 Gy) irradiation before enucleation has 
had no effect on survival.70,71  
 
Thermotherapy given through dilated pupil (transpupillary thermotherapy), has been shown to be an 
effective treatment for selected small choroidal melanomas and in combination with brachytherapy 
also for larger ones.72-74 Tumor resection under arterial hypotension in otherwise healthy patients is 
another type of eye conserving treatment of uveal melanoma.41,75 Studies on gamma-knife techniques 
and photodynamic therapy have more recently been published.76,77 Due to small sample sizes and short 
follow-up time their eventual place in clinical ophthalmic oncology are not yet established.  
 
Treatment of metastatic uveal melanoma is often, if not always, unsatisfactory.29 Chemotherapy and 
chemoembolization to the hepatic artery with or without interferon have potentially lengthened 
survival to a mean of 12 months and up to 20% of metastases have regressed at least partially during 
treatment, but the disease has always later progressed and killed the patient.29-31,78,79 Only very few 
patients treated with surgery for a solitary, slow growing metastasis have survived for long term.80-82 A 
preliminary non-randomised study on dietary biological adjuvant therapy for primary intraocular 
melanoma suggested an improved survival, but the series contained only nine patients and follow-up 
time was relatively short.83 
 
1.5 Natural course of the disease 
 
Because uveal melanomas are treated promptly after diagnosis,20 the natural course of uveal melanoma 
is a matter of dispute. In several series of treated patients the 10-year cumulative melanoma-specific 
survival has been close to 60%, and it has thereafter decreased by about 1% per year.84-86 Deaths from 
metastatic uveal melanoma are regularly reported even decades after enucleation.87,88 Uveal melanoma 
has a remarkably strong tendency to produce liver metastases.10,12,89,90 Liver is involved as the only 
metastatic site in half of the patients, and only 5% of patients who have disseminated uveal melanoma 
do not have eventual metastasis in the liver.10,12,90 Other preferred sites for metastases are skin, lung, 
and bone.10,12,89,91 The median expected lifetime after metastatic uveal melanoma is diagnosed is in 
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most cases less than a year, but single patients with few, slowly growing metastases have survived 
even for three to four years.30,82 
 
As documented in many series, the melanoma-specific mortality is highest within two to three years 
after enucleation, which lead Lorenz E. Zimmermann to suggest that removal of the eye might cause 
tumor dissemination and increase melanoma-specific mortality.92,93 An inferred natural history of uveal 
melanoma is traditionally based on tumor size and how long it takes for a tumor to grow from a 
medium-sized to a large one, because large series of untreated patients have not been published.93,94 
The average survival time of patients who have refused all treatments for intraocular melanoma have 
been five years and some patients have survived even 15 years.34,94 Ian McLean and collaborators have 
estimated that it takes 7 years for a small tumor (LBD <10 mm) to grow into a large one (LBD >15 
mm).93 Willem Manschot on the other hand, has strongly supported radical therapy (enucleation) even 
for small tumors (<7 mm), because they might be treated before dissemination has occurred.32,95,96 
Empirical data based on tumor doubling times of metastases, however, suggest that clinically 
undetectable micrometastases likely initiate on average two to three years before treatment for primary 
tumor is given.28 To improve survival of patients with uveal melanoma, it seems prudent to minimise 
delays in treatment of primary tumor as much as possible and to screen high-risk patients for metastatic 
disease, hoping that eventual adjuvant therapy might be more efficient than current chemotherapy 
regimens are for distant mestastasis.12,53,55 
 
The natural course of the disease is, however, also modulated by tumor and host characteristics, 
because a patient with a large tumor may survive much longer than a patient with a small tumor and 
this also applies to other poor prognostic factors as well.    
  
2. PROGNOSTIC INDICATORS OF UVEAL MELANOMA 
 
2.1 PATIENT-RELATED FACTORS 
 
2.1.1 Age and sex 
 
Increasing age is associated with poorer melanoma-specific survival, which may result from a 
weakened immune system.97,98 The short term prognosis (5-year) of young patients (< 20 years) is 
better than that of adults, but the long-term prognosis (15-year) is similar to that of adults.99,100 Whether 
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women have better survival than men, as some studies suggest,101,102 has remained controversial since 
many studies have not found such a relationship.103-106  
 
2.1.2 Reproductive factors  
 
Some uveal melanomas have progressed during pregnancy, possibly by coincidence, but the 
childbearing history and the use of oral contraceptives do not increase the risk for metastatic 
disease.47,48,107 In fact, a recent paper suggested that childbearing may even improve prognosis in uveal 
melanoma.101 The protective influence of parity was highest in the early period following treatment 
and it even increased with the number of live births. In Cox regression, however, men and nulliparous 
women had only borderline higher risk for metastatic death than women who had given birth.101    
 
2.1.3 Immunological factors  
 
The onset of clinical metastatic disease many years after enucleation and the rare spontaneous 
regression of uveal melanoma have been cited as indirect evidence for a role of the immune system in 
progression of this tumor.108 This could be mediated by tumor-infiltrating and circulating immune 
cells. Of uveal melanoma infiltrating lymphocytes, the majority is CD4+ and CD8+ T-cells that may 
modulate the immune response and that may have direct cytotoxic effects on tumor cells.109,110 A dense 
infiltration of lymphocytes has been associated with shorter survival time by univariate analysis.102,109 
Tumor-infiltrating macrophages have not been studied to the same extent than lymphocytes, but some 
reports have mentioned sparse to marked infiltration by CD68+ macrophages in uveal melanoma.110-112 
The possible functions of macrophages in malignant tumors are thought to be variable and even 
contradictory; on one hand they might be tumoricidal, on the other hand they might promote tumor 
growth.113,114 Other leukocytes, such as granulocytes, B-lymphocytes, and natural killer cells seem to 
be present to a smaller extent than T-lymphocytes and macrophages in these tumors and their role is 
even more uncertain.115 
 
Human leukocyte-associated (HLA) antigens are essential for immune cells to recognise neoplastic 
cells.116 Of HLA class I antigens, low expression of HLA-A and HLA-B antigens in uveal melanoma 
has been associated with a better survival.117,118 This inverse correlation was explained by dual 
functions of HLA antigens. Whereas lymphocytes need HLA antigens to recognise tumor cells, 
presence of HLA class 1 antigens may block natural killer cell-mediated lysis of tumor cells.116,117 A 
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high expression of HLA-B was associated with the epithelioid cell type and inversely correlated with 
expression of c-myc oncogene.119 
 
2.1.4 Miscellaneous factors  
 
The presence of cutaneous dysplastic nevi not only increases the risk for developing primary uveal 
melanoma, but it may also be associated with the epithelioid cell type, a traditional poor prognostic 
indicator of uveal melanoma.45,120 In a large series of proton beam irradiated uveal melanomas, patients 
with blue and gray irises were at 1.90 times higher risk of dying of metastatic uveal melanoma than 
patient with brown irises.38 No relationship was found between smoking and risk of metastatic 
deaths.121    
 
2.2 TUMOR-RELATED FACTORS 
 
2.2.1 Tumor location 
 
Anterior tumor location within the ciliary body or with ciliary body involvement has often been linked 
to increased melanoma-specific mortality.27,85,86,97,102,122 Choroidal tumors extending to the ciliary body 
tend to be larger than posterior ones (posterior to the equator), but tumor size alone does not explain 
such an association, because ciliary body involvement has been an independent predictor of survival in 
many multivariate models in addition to LBD.86,97,122,123 A high frequency of microvascular networks 
and chromosomal changes in some datasets, especially monosomy of chromosome 3 and gain of 
chromosome 8, have been put forward as factors underlying the more aggressive nature of ciliary body 
melanomas.49,106,123-125 Iris melanomas on the other hand, metastasize very rarely and the reported 10-
year mortality is only 5%.17   
 
When a ciliochoroidal or iris melanoma that invades the ciliary body is diagnosed, the original uveal 
compartment where the tumor initiated may be difficult to resolve. The extent of ciliary body 
involvement graded by the proportion of the tumor base lying anterior to the ora serrata was recently 
put forward as a diagnostic criterion.27 According to this study, a melanoma of presumed ciliary body 
origin (>50% tumor base anterior to the ora serrata) had 1.6 to 2.3 times higher chance to metastasize 
than a choroidal (<50% tumor base anterior to the ora serrata) tumor.27 Of posterior tumors, those 
located adjacent to the optic disc may have a worse prognosis, related to more frequent extrascleral 
extension.57  
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2.2.2 Extraocular extension 
 
The fibrous outer layer of the eye, the sclera, resists the growth of intraocular melanoma effectively, 
but sometimes intraocular melanoma invades the orbit through emissaries such as posterior ciliary 
arteries and vortex veins.3 Juxtapapillary choroidal melanoma may invade the orbit adjacent to the 
optic disc and, rarely, thorough the optic nerve.3 Choroidal and ciliary body melanomas that infiltrate 
the chamber angle may grow to subconjunctival tissues to cause local lymph node metastases which 
otherwise do not develop from uveal melanoma.126 Intraocular melanoma disseminates mostly 
hematogenously, and only when the anterior scleral wall is broken, tumor cells have access to 
conjunctival lymphatics.2,11  
 
Extraocular extension is an unfavourable prognostic sign for which conservative treatment modalities 
are traditionally not recommended and radical surgery combined with irradiation therapy is often 
needed.127,128 If extraocular extension is small (<3 mm), conservative methods such as plaque or 
charged particle irradiation may still be effective.129  
 
2.2.3 Tumor size 
 
One of the most consistent prognostic indicators for metastases of uveal melanoma is tumor 
size.84,85,102,103,105,122,130,131 Of various ways to classify according to tumor size (Table 1), largest basal 
tumor diameter (LBD) and tumor height are the most widely used.84,102,103,105,122 According to LBD 
melanomas are divided into small (≤10 mm), medium-sized (10-15 mm), and large (>15 mm) 
ones.102,103 Evaluation of tumor volume and recently presented computer-assisted quantification of 
cross-sectional tumor area are other ways to measure tumor size.132,133 The results have been most 
consistent for LBD and, from a clinical point of view, LBD can be conveniently measured by indirect 
ophthalmoscopy and B-scan ultrasonography.41 LBD is also related to success of local resection and 
tumor height largely determines the dose in plaque brachytherapy.41 Formal classifications, such as 
TNM system and COMS classification take also into account tumor height (Table 1). The 10-year 
melanoma-specific mortality is as high as 60% among large tumors, whereas it is only 10-15% among 
small melanomas.25,85,86,103,134  
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Table 1. Classifications of tumor size in choroidal and ciliary body melanomas 
----------------------------------------------------------------------------------------------------------------------------- 
Category 
 ------------------------------------------------------------------------------------------- 
Classification Small Medium-Sized Large 
----------------------------------------------------------------------------------------------------------------------------- 
TNM LBD ≤ 10 mm and LBD >10-15 mm and  LBD > 15 mm and 
  Height ≤ 3 mm (T1) Height >3-5 mm (T2) Height > 5 mm (T3) 
 
Collaborative LBD ≤ 16 mm and LBD ≤ 16 mm and LBD > 16 mm and 
Ocular Melanoma Height < 2.5 mm Height ≥2.5 but ≤ 10 mm Height ≥ 2 mm 
Study  or Height > 10 mm  
 
Common LBD ≤ 10 mm LBD >10-15 mm LBD >15 mm 
Classification 
based on LBD102  
 
Tumor Cross- < 16 mm2 ≥ 16 mm2  but ≥ 61.4 mm2 
Sectional Area133 < 61.4 mm2 
----------------------------------------------------------------------------------------------------------------------------- 
 
2.2.4 Cell type 
 
G. R. Callender described comprehensively the cytological features of uveal melanoma cells in 
1931.135 The classification that still carries his name is based on the shape and other cytological 
features of melanoma cells, but it has since then been modified by ophthalmic pathologists of the 
Armed Forces Institute of Pathology (AFIP). Callender defined two main cell types: the spindle and the 
epithelioid cells. Spindle cells typically grow in a compact cohesive fashion and they were originally 
subdivided into spindle-A and spindle-B type.3,135 Patients with spindle-A type melanoma have a 
significantly more favourable clinical course than patients with spindle-B type melanoma.3,131 In the 
modified AFIP classification, the spindle-A cell type melanoma was recorded a nevus rather than a 
malignant melanoma, and the diagnosis of spindle cell type melanomas required spindle-B cells.136 The 
malignant potential of less cohesive epithelioid cells is well established in many independent 
studies.86,102,122,130,132 In addition, the original Callender classification included mixed, fascicular, and 
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necrotic types of uveal melanoma. The presence of necrotic cell type indicated higher mortality than 
presence of non-necrotic cell types, but the association was non-significant after controlling for tumor 
size.137   
 
A matter of controversy has been which amount of epithelioid cells is to be considered a sign of poor 
prognosis.138-140 In recent prognostic studies, the mixed and epithelioid types have often been 
combined in the same category, and the presence of even a single well-defined epithelioid cell in a 
section may lead to classifying it as nonspindle instead of spindle.102,141,142 This two-category 
classification is also conveniently handled in multivariate analysis.102 
 
2.2.5 Tumor pigmentation 
 
Heavy tumor pigmentation has been associated with decreased survival in several univariate studies, 
but different classifications of the amount of pigmentation make comparisons between cohorts 
difficult.85,105,131,132 The relationship between heavy tumor pigmentation and two other prognostic 
indicators, epithelioid cell type and large LBD suggests that prognostic significance of tumor 
pigmentation may be secondary to other tumor characteristics.111 Cutaneous melanomas with high 
melanin content are more resistant to irradiation than lightly pigmented ones, but the significance of 
this observation as regards to uveal melanoma is unknown.143 
 
2.2.6 Microvascular patterns 
 
Studies on tumor blood vessel morphology in uveal melanoma were introduced by Robert Folberg and 
colleagues in 1992 when they presented nine morphological types of microvessel architecture which 
they designated microvascular patterns.144 The patterns were identified by fuorescein-conjugated Ulex 
europaeus I using laser scanning confocal microscopy and by periodic acid-Schiff stain (PAS) that 
stains basement membrane and collagen.144,145 However, bleaching of melanin by permanganate and 
PAS staining without hematoxylin counterstain were found as effective and inexpensive methods of 
demonstrating microvessels.102,144 PAS stains also melanoma cells, but a use of green filter enhances 
contrast of PAS-positive structures helping in regognising of microvessels.144,146 According to the 
original classification144: the normal pattern consists of normal uncompressed choroidal vessels. The 
silent pattern contains no apparent tumor vessels. The straight pattern is comprised of randomly 
oriented straight vessels that are not linked with each other. The parallel pattern included straight 
vessels that are arranged parallel to one another. The parallel with cross-link pattern contains vessels 
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of parallel pattern that are also linked to each other. The arcs and arcs with branching patterns are 
curves of vessels that failed to form loops. The loop pattern consists of vessels that are completely 
closed. The diameter of loops ranged from 14 µm to 157 µm in dataset of 30 loops from different 
tumors.144 The network pattern is composed of at least three back-to-back closed loops. By definition, 
if networks are present, loops are present.144 
 
In the matched case-control study of 40 patients, patients who survived over 15 years had more 
frequently the normal and silent pattern than patients who died of metastatic uveal melanoma.144 
Furthermore, melanocytic nevi did not contain any parallel with cross-linking, arcs, arcs with 
branching, loops, or networks, consistent with the finding that these latter patterns would be associated 
with melanoma deaths.147 In fact, patients who died of uveal melanoma had more frequently parallel, 
parallel with cross-link, loop, and network patterns than patients who had survived long.147 These 
melanoma-associated microvascular patterns were found more frequently in ciliary body tumors than 
in choroidal ones.123 A laboratory-based follow-up study of 234 patients who had an eye removed 
because of uveal melanoma showed melanoma-specific mortality to be higher among patients who had 
parallel vessels, parallel vessels with cross-links, arcs, arcs with branching, loops, and networks than 
among patients who lacked these microvascular patterns.102,123 In multivariate analysis, presence of 
networks and parallel vessels with cross-links gained independent prognostic significance.102 These 
two studies inspired a series of confirmatory studies from independent, sometimes sceptical groups that 
all substantiated the prognostic significance of microvascular patterns in uveal melanoma (Table 2).148 
104,141,149
  
 
In cutaneous and conjunctival melanoma parallel vessels with cross-linking or networks gained 
independent prognostic significance in multivariate analysis adjusted for the important conventional 
prognostic indicator, tumor thickness.150,151 All nine microvascular patterns were found in these tumors 
proving that formation of these microvascular patterns is not restricted to intraocular melanoma. 
 
Folberg´s laboratory found that tumor cells of malignant uveal and metastatic cutaneous melanoma are 
able to form microvascular patterns, in particular microvascular loops and networks in vitro without 
presence of endothelial cells.152 The active role of uveal melanoma cells in production and remodelling 
of ECM was supported by the observation that melanoma cells are capable of generating type VI 
collagen.153 In vitro derived microvascular patterns were demonstrated to conduct dye and thus might 
be functional in vivo.152 This concept of blood vessel formation without endothelial cells, now called 
vasculogenic mimicry, differs in many respects from the traditional view of tumor angiogenesis, in 
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which new vessels are formed from pre-existing ones by proliferation of endothelial cells.152 
Preliminary investigations have revealed differences in gene expression between melanomas that form 
microvascular networks and melanomas that are incapable of doing that.13 Recently, a specific profile 
of protein tyrosine kinases was associated with the ability of uveal melanoma cells for vasculogenic 
mimicry.154 
 
A panel of endothelial markers including Ulex europaeus I lectin, CD31, CD34, and KDR failed to 
reveal distinct positive immunostaining of the walls of uveal melanoma microvessels supporting a 
different nature from endothelial-lined tumor vessels.152 The authors interpreted the positive 
immunoreaction they observed to reside in the vascular contents and in some cross-reacting tumor 
cells.152 Tumor cell-lined blood channels are demonstrated by several independent groups,144,155,156 but 
the functional evidence and the connection between tumor cell-lined channels and intratumoral 
microvessels are questioned.148,157,158 In order to resolve the contradictory issues on microvascular 
mimicry and to define its generalizations, many experimental studies worldwide are in progress. 
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2.2.7 Microvascular density 
 
The concept of microvascular density (MVD) and methods for measuring it from the highest area of 
vascularization were popularised in the early 1990´s.159,160 High numbers of immunolabeled 
microvessels counted from the area of densest vascularization called a “hot spot” indicated increased 
risk for metastatic death and this was taken as evidence of active angiogenesis in many types of 
cancer.159,161 The majority of such studies have shown that high MVD is associated with shorter 
survival, but contradictory reports are not uncommon.161 In particular, reports of cutaneous melanoma 
have been controversial.162,163 Initial studies suggested that high vascularization has a significant 
influence on survival, but no consensus of its eventual significance has been achieved.162,163 This may 
be due to the fact that cutaneous melanoma cells can also use lymphatic vessels in their dissemination, 
which likely blurs any association with the density of microvessels.164 The theoretical background of 
MVD has been criticised for lack of well proved link with angiogenesis, poor reproducibility, and 
questionable specificity of some of the antibodies used in highlighting microvessels.2,163,165  
 
Foss and colleagues reported that high MVD was associated with a shortened survival of patients with 
uveal melanoma.105 The study population comprised of 116 patients with uveal melanoma and the 
series was enriched with an unspecified number of patients who had died of metastatic uveal 
melanoma.105 They did not find any relationship between microvascular patterns and survival in their 
data set after adjusting for MVD.148 It was found that MVD was higher in tumors with microvascular 
loops and networks, suggesting that the effect on prognosis of microvascular patterns might be 
secondary to high MVD.148 Two other groups have presented opposite results on the prognostic 
significance of MVD in uveal melanoma.166,167 A follow-up study of 63 tumors failed to document any 
survival difference between tumors with different microvessel counts,166 which was also the case in a 
small follow-up study of 40 uveal melanomas.167 
 
2.2.8 Cell-matrix interaction 
 
Interaction between tumor cells and surrounding stroma are considered essential for tumor progression 
and dissemination. A decade ago it was documented that some uveal melanomas co-express vimentin 
(typical among melanocytes) and cytokeratin 8 and 18 (typical among carcinomas) intermediate 
filaments.142 Recently it was shown in vitro that uveal melanoma cells coexpressing both types of 
intermediate filaments had a 6-fold capability of invasion as compared to melanoma cells that express 
only vimentin.168 Cells that coexpress both intermediate filaments were named ”interconverted” 
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cells.168,169 Clinical evidence for an association between the interconverted phenotype and prognosis is 
still missing, perhaps due to the small number of tumors studied so far.142 
 
Of cell adhesion molecules, neural cell adhesion molecule (NCAM) is preferentially expressed on 
rapidly metastasising uveal melanomas.170 The HNK-1 epitope, which is part of NCAMs, was more 
frequently expressed in larger tumors, but seldomly in liver metastases.170 Another report, however, 
failed to document any relationship between NCAM expression and survival, but instead reported that 
intercellular cell adhesion molecule-1 (ICAM-1) was linked to the development of metastases.171 
Expression of VLA-2 integrin receptor was associated with the presence of microvascular networks, 
but none of the integrin receptors studied (VLA-2, VLA-3, and alpha (v)) seemed to have prognostic 
significance.106 
 
Both primary and metastatic uveal melanomas lack estrogen and progesterone receptors and potential 
effects of anti-estrogens on uveal melanoma can not be mediated by conventional mechanisms.112,172 
Positive cytoplasmic immunostaining with an antibody to estrogen receptors (ER) was shown to be 
from cross-reacting CD68-positive macrophages.112 The expression of epidermal growth factor 
receptor (EGFR) in uveal melanoma cell lines correlated with metastatic potential and liver-targeted 
metastasis.173 Moreover, EGFR expression correlated with metastatic death in a small clinical series of 
uveal melanomas.174 However, EGFR expression in uveal melanoma may be confined to tumor-
infiltrating macrophages.175 
 
Expression of matrix metalloproteinase-2 (MMP-2) was recently linked to decreased uveal melanoma-
specific survival, but the sample size was not large enough to test independent prognostic significance 
of MMP-2 in multivariate analysis.176  
 
2.2.9 Markers of cell proliferation  
 
The development of antibodies to proteins, such as PC-10 and Ki-67, which characterise cells that are 
in the proliferative phase of the cell cycle, started a sequence of studies to resolve the prognostic 
significance of proliferating tumor cells in uveal melanoma and in other cancers.177-179 A high fraction 
of  PC-10 and Ki-67 immunopositive uveal melanoma cells has been associated with decreased 
melanoma-specific survival in many cohorts of uveal melanoma.177-180 In one particular study, a high 
fraction of PC-10 immunopositive tumor cells was associated with a 40% increase in 10-year 
melanoma-specific mortality.179 Also a high PC-10 count was an independent prognostic factor by 
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multivariate analysis adjusted for LBD, presence of microvascular networks, and the mean diameter of 
the largest nucleoli.104 The high expression of cyclin D1, a protein involved in the cell cycle, indicates 
an unfavourable outcome in uveal melanoma.181 Moreover, cyclin D1 positivity was associated with 
the epithelioid cell type and a high index of Ki-67 positive tumor cells.182,183 
 
2.2.10 Nuclear morphometry 
 
A high number of mitoses has been associated with increased mortality in uveal melanoma.86,132,180 
Several studies have indicated that large indices of cytomorphometric parameters, such as 
measurements of nuclear and nucleolar area from randomly selected cells are associated with higher 
than average melanoma-specific mortality.84,184-187 In particular, the mean of the ten largest nucleoli 
and the standard deviation of nucleolar area have retained independent prognostic value in multivariate 
analyses, and computer-assisted measurements have been reproducible between different 
laboratories.184-186 However, the methodology of nuclear morphometry assessment is still controversial 
and recently silver-stained sections were found superior to HE-stained sections.188 Regarding the 
relative importance of nuclear morphometry and other tumor characteristics, Pe’er and associates 
reported that the network and the parallel vessels with cross-link microvascular patterns were more 
powerful prognostic indicators than cytomorphometric indices, such as mean of the ten largest 
nucleoli, in their data set.189 
 
2.3 CYTOGENETICS 
 
2.3.1 DNA aneuploidy 
 
Flow cytometry can be used to assess the DNA content and proliferative activity of tumor cells.190 A 
DNA content deviating from the normal amount (diploid vs. aneuploid) reflects the genetic instability 
of tumor cells and impaired control of the cell cycle which are characteristics of malignant cells.190 
Aneuploid DNA and a high fraction of cells in the S-phase of the cell cycle have been associated with 
the epithelioid cell type and decreased survival in uveal melanoma.191,192  
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2.3.2 Chromosomal abnormalities  
 
Specific chromosomal changes, in particular loss of one copy of chromosome 3 and gain of the long 
arm of chromosome 8 are emerging as particularly significant prognostic indicators in several 
independent studies of inconsecutive series of surgically treated uveal melanomas.51,124,193,194 These 
chromosomal changes are more frequent in tumors with ciliary body involvement than in choroidal 
tumors, which may explain the worse prognosis of ciliary body melanomas as compared to choroidal 
melanomas.124,125 So far, studies of chromosomal changes concern predominantly large melanomas, 
because small and medium-sized melanomas are mostly treated by irradiation.124,194 Thus, the results 
can not yet be generalised to all uveal melanomas, but chromosomal changes certainly play an 
important role in tumor progression. A study based on a consecutive series of uveal melanomas that are 
studied regardless of tumor size is needed to establish the role and sequence of chromosomal changes 
among uveal melanomas of all sizes. 
 
Recently, analysis of the partial deletion of the long and short arm of chromosome 3 suggested the 
presence of tumor suppressor gene locus at 3q24-q26 and 3p25.195 The long-term follow-up data were 
not yet available for patients whose tumor had a partial deletion. The growth restricting effect of TGFβ 
may be lost in deletions involving chromosome 3p22 in which the gene for TGFβ receptor is 
located.196 An abnormality of the TGFβ pathway were found in 61% of uveal melanomas, but authors 
did not determine monosomy 3 to TGF β function.196 
 
2.4 MOLECULAR PATHOLOGY  
 
2.4.1 Oncogene activation 
 
A potential tumor-suppressor gene nm23 has been detected in uveal melanomas that were small in size 
and showed no extraocular extension.197,198 In an animal model, the expression of nm23 gene was 
associated with reduced metastatic potential and fewer liver metastases.197 No association was found 
between nm23 expression and conventional prognostic indicators, such as cell type and ciliary body 
involvement.198  
 
A high expression of the c-myc oncogene is known to have an influence on survival in a number of 
cancers, including cutaneous melanoma. In case of uveal melanoma, the results have been opposite; a 
low expression of c-myc is associated with higher mortality.199,200 Nuclear c-myc expression was found 
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in each of 71 studied uveal melanomas, but cytoplasmic c-myc expression was much more prominent 
than nuclear expression in another study.180,200 The presence of c-myc positive cells was associated 
with decreased survival after adjusting for LBD and Ki-67 positive cells in multivariate analysis.180  
 
2.4.2 Programmed cell death  
 
Expression of Bcl-2 protein, a proto-oncogen that blocks programmed cell death (apoptosis), has been 
documented convincingly in uveal melanoma, but its prognostic significance is lacking.180,200-202 On the 
other hand, very few melanomas have been shown to express p53, a nuclear phoshoprotein that 
induces apoptosis and cell-cycle arrest.200,202,203 The treatment effect of irradiation and transpupillary 
thremotherapy may be mediated by apoptosis.200,203-205 Dendritic cells stimulated effectively 
lymphocyte proliferation and phagocytosed melanoma cells after uveal melanoma cells had undergone 
apoptosis due to irradiation.204 This finding suggested that dying intraocular melanoma can serve as an 
autologous stimulus for immune cells against tumor cells.204 Recently, overexpression of -Catenin, a 
molecule involved in cell adhesion and signal transduction, induced apoptosis in uveal melanoma 
cells.206 
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3. AIMS OF THE PRESENT STUDY 
 
The purpose of this study was to search for and evaluate new prognostic indicators for metastatic death 
in a well-documented and population-based series of Finnish patients with malignant choroidal and 
ciliary body melanoma.  
 
In the first phase of the thesis, two hypothesis-confirmatory studies were designed and undertaken to 
confirm or contradict an association between melanoma-specific survival and presence of 
microvascular loops and networks and microvascular density.  
 
In the second phase of the thesis, two hypothesis-generating studies were performed to find out 
whether tumor-infiltrating macrophages and ezrin immunoreactivity in melanoma cells are associated 
with prognosis.  
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4. MATERIALS AND METHODS 
  
4.1 PATIENTS 
 
4.1.1 Recruitment and follow-up 
 
A consecutive cohort of uveal melanoma patients was collected from the diaries of the Ophthalmic 
Pathology Laboratory, Department of Ophthalmology, Helsinki University Central Hospital. A total of 
170 consecutive patients, all Caucasian with a choroidal or ciliary body melanoma were enrolled from 
the years 1972 to 1981. During that period, enucleation was the standard treatment for all but the 
smallest uveal melanomas, and all eyes enucleated in the district of the Helsinki University Central 
Hospital were submitted to its Ophthalmic Pathology Laboratory. Even though a smaller number of 
uveal melanomas per year were treated in other hospitals than Helsinki University Hospital, the series, 
based on its files, is essentially unselected and representative of all malignant uveal melanomas 
diagnosed in its area.  
 
Three patients were permanently excluded from the analysis: one patient due to metastatic cutaneous 
melanoma to the choroid, one patient due to the removal of choroidal melanoma under autopsy, and 
one patient because of iris melanoma. Thus, 167 patients with choroidal or ciliary body melanoma 
were left in the analysis.   
 
Complete follow-up data for each patient was assembled in January 1997 from data retrieved from the 
Finnish Population and Cancer Registries, from patient charts of all hospitals where they had been 
treated for uveal melanoma, its metastases and other malignant tumors, from pathology laboratories, 
and from death certificates. A questionnaire concerning treatment for malignant tumors was sent to all 
living patients in 1997. The data on patients alive in 1997 was updated in December 1999 with the help 
of the Finnish Population Registry. Studies on ezrin and tumor-infiltrating macrophages are based on 
follow-up data updated in December 1999. 
 
4.1.2 Exclusion criteria 
 
The following exclusion criteria were adhered to throughout the study: Melanomas that were more 
than 50% necrotic, and, by analogy, specimens in which either less than 50% of the original melanoma 
remained or the remaining part was entirely on the vitreal side of Bruch's membrane. Altogether, 33 
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(20%) melanomas had to be excluded from the analysis, 15 (9%) melanomas because of more than 
50% consisted of necrotic tumor, 16 (10%) melanomas either because of a small size of (<50%) 
remaining tumor or its location entirely on the vitreal side of Bruch’s membrane, and two (1%) 
melanomas because of missing paraffin blocks. Thus, 134 (80%) patients were included in 
histopathological examination. The necrotic tumors were, however, included in the analysis of tumor-
infiltrating macrophages. Patients who had a second primary tumor other than uveal melanoma were 
not excluded, because histopathologic confirmation of the cause of death was available for all of them. 
 
4.1.3 Reinvestigation of the cause of death 
 
In order to analyse melanoma-specific mortality more reliably than in a cancer registry based-analysis, 
an attempt was made to differentiate all melanoma deaths from other deaths. To improve the accuracy, 
all tumor deaths irrespective of primary site and all other non-tumor deaths were personally reviewed. 
The clinical reliability of the cause of death was evaluated in the following descending order: autopsy, 
surgical biopsy, fine-needle biopsy, imaging, and clinical charts.  
 
Table 3. Evidence for the cause of death among 130 patients who died during follow-up 
------------------------------------------------------------------------------------------------------------------------ 
 Metastatic Melanoma Other Tumor Deaths Other Deaths 
 N=80 (%) N=9 (%) N=40 (%) 
 ----------------------------------------------------------------------------- 
Autopsy 27 (34) 2 (22) 12 (30)  
Biopsy 27 (34) 7 (78) -   
Fine-Needle Biopsy 13 (16) - - 
Imaging 10 (12) - - 
Clinical   3   (4) - 30 (70)  
 
The cause of death is unknown in one (1%) case 
------------------------------------------------------------------------------------------------------------------------ 
 
The most reliable evidence of tumor death was autopsy on 29 (33%) patients, a surgical biopsy on 34 
patients (38%), a fine-needle aspiration biopsy on 13 (15%) patients, imaging on 10 (9%) patients (four 
by abdominal ultrasonography, three by liver scan, two by computed tomography of the liver, and one 
by chest x-ray), and clinical charts on three (3%) patients (Table 3). Histopathological material from 
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metastases could be retrieved from 32 of the 34 surgical biopsies and from 27 of the 29 autopsies 
performed on tumor patients. Moreover, no evidence of cancer was found in 12 autopsies that were 
performed on 40 patients who presumably died of other causes (Table 3). Altogether, autopsy was 
performed on 41 (32%) patients who died during follow-up period. 
 
4.1.4 Comparative analysis of primary and metastatic melanoma 
 
In order to correlate properties of primary tumors with metastatic tumors, a study on microvascular 
patterns and density was undertaken among patients who had died of metastatic uveal melanoma. Of 
134 patients, who fulfilled the inclusion criteria for the study of MVD and microvascular loops and 
networks, 63 (47%) died of metastatic uveal melanoma during follow-up. Of these 63 patients, 42 
(67%) subjects underwent either surgical biopsy or autopsy. Because of delayed fixation and autolysis, 
specimens taken at six autopsies had to be excluded from the analysis. The three smallest biopsies were 
not large enough to assess microvascular density from an area of 0.313mm2 used in this thesis, leaving 
33 of the 63 (52%) patients to the comparative study of microvascular properties of primary and 
metastatic uveal melanoma.  
 
4.2 IMMUNOHISTOCHEMISTRY 
 
4.2.1 Monoclonal antibodies 
 
Primary mouse antibodies to human antigens were purchased, except the mAb 3C12 to ezrin that was 
received from the collaborators (Table 4). All used mAbs were previously documented to work in 
paraffin sections.  
 
4.2.2 Immunoperoxidase staining  
 
 The paraffin blocks were cut at 5 µm and the slides were randomly coded by an outside laboratory 
technician. The code was broken after both the final histopathologic and follow-up data were ready for 
analysis, all investigators being masked to the outcome of individual patients until that time. 
  
The immunohistochemical staining was done using a commercial version (Vectastain ABC Elite Kit, 
Mouse IgG, Vector Laboratories, Burlingame, CA) of the avidin-biotinylated peroxidase complex 
(ABC) method.207 The sections were deparaffinized in xylene and rehydrated in an ethanol series. 
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When heat-induced antigen retrieval was needed, the specimens were placed in a jar filled with 10 mM 
sodium citrate buffer (pH 6.0, adjusted with 2 N NaOH), and heated in a water-bath for 15 min at 
95°C.208 The jar was allowed to cool for 20 min at room temperature after heating. When proteolytic 
antigen retrieval was needed, the slides were treated with 0.4 % (w/v) pepsin (2500 FIP U/g, E. Merck, 
Darmstadt, Germany) in 0.01 M hydrochloric acid for 15 min at 37°C to reduce background and to 
enhance the intensity of specific staining.209 
  
Endogenous peroxidase activity was consumed by treating the sections for 30-min in methanol 
containing 0.5 % (v/v) hydrogen peroxide. They were then incubated with normal horse or goat serum 
(Vectastain ABC Elite Kit, diluted 1:50) in a moist chamber for 30 min at room temperature. All 
immunoreagents were diluted with PBS (pH 7.0) containing 2.0 % (w/v) bovine serum albumin (BSA; 
E. Merck, Darmstadt, Germany). The sections were washed three times for 10 min in PBS between 
each step. Incubation with the primary mAbs was carried out in a moist chamber for overnight at 5°C. 
Subsequently, the sections were incubated with biotinylated horse anti-mouse or goat anti-rabbit IgG 
antiserum (Vectastain ABC Elite Kit; diluted 1:200) and then with the ABC (Vectastain ABC Elite Kit 
reagents A and B, both diluted 1:160) in a moist chamber for 30 min at 37°C. The peroxidase reaction 
was developed with 3',3'-diaminobenzidine tetrahydrochloride (Sigma; 150 mg in 16 ml dimethyl-
sulfoxide and 200 ml PBS containing 0.03 % (v/v) hydrogen peroxide). Coverslips were mounted with 
Aquamount (BDH Chemicals, Poole, UK). 
 
4.2.3 Bleaching of melanin 
 
Chromogens, such as 3',3'-diaminobenzidine tetrahydrochloride and 3-amino-9-ethylcarbazole that 
yields a dark brown reaction and a brick red reaction product, respectively, can not be differentiated 
easily from melanin of pigmented tumors.112 Melanin can be removed with 0.25% potassium 
permanganate followed by 5% oxalic acid,144,210 but bleaching performed prior to immunoperoxidase 
staining often alters antigenicity and significant number of antibodies fail to work properly anymore. 210 
Potassium permanganate bleaching is suitable, however, for removal of melanin prior to hematoxylin-
eosin and periodic acid Schiff stainings.102,144 Thus, in order to visualise positive immunoreaction in 
pigmented tumors reliably, melanin was bleached by incubating the sections in 3.0 % (v/v) hydrogen 
peroxide and 1.0 % (w/v) disodium hydrogen phosphate for 18 h at room temperature.211 This 
procedure obviates any change in antigenicity due to the bleaching.211 
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4.3 ASSESSMENT OF TUMOR CHARACTERISTICS 
 
4.3.1 Baseline characteristics  
  
The cell type was registered according to the modified Callender classification (spindle, mixed, 
epithelioid) from a hematoxylin-eosin stained section.136 If the original histopathology report 
mentioned the presence of epithelioid cells in a tumor registered as spindle cell type, this tumor was 
reclassified to the nonspindle type. The location (choroidal, ciliary body with or without choroidal 
involvement), the largest basal tumor diameter (LBD) and the height of the tumor measured in mm, 
and the presence or absence of extraocular extension were taken from the original pathology reports 
and checked to be consistent with the sections studied. The degree of pigmentation of each tumor was 
graded semiquantitatively by sorting out unstained 5-µm-thick paraffin-embedded sections of whole 
tumor into three groups that represented amelanotic to weak, intermediate, and strong pigmentation. 
The sorting was done simultaneously for the entire set of specimens on a sheet of white tissue paper 
under a light without magnification. 
 
4.3.2 Microvascular loops and networks 
 
Sections were stained with periodic acid-Schiff (PAS) without hematoxylin counterstain in order to 
identify loops and networks that were associated with increased melanoma-specific mortality in 
previous studies.102,104,141 All sections irrespective of the amount of melanin were bleached by 
potassium permanganate before PAS staining. Two observers independently examined the slides under 
a light microscope using a dark green filter (Wratten No 58, Kodak, Rochester, NY), and recorded the 
presence or absence of loops and networks. Prior to analyzing the randomly coded study slides, the 
criteria to be used were agreed upon, and a set of slides, not included in the study series, was examined 
under a double-headed microscope. Disagreements in registering vascular patterns in the study series 
were resolved in the same manner. 
 
4.3.3 Microvascular density 
 
Microvessels were immunostained with mAb QBEND/10 to the CD34 epitope of endothelial cells and 
polyclonal rabbit antibodies to FVIII-RAg, and microvessels with a muscular layer were 
immunostained with mAb 1A4. Microvessels were counted from three separate, most highly 
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vascularized areas ("hot spots") according to Foss and colleagues.105 Scanning the entire 
immunostained tumor at X100 magnification identified the three areas. Vessels were then counted at 
X200 magnification using an eyepiece with an etched square graticule (Olympus, WK 10x/20L-H, 
Tokyo, Japan). The area of the graticule was 0.313 mm2 as measured with an object micrometer (Ernst 
Leitz Gmbh, Wetzlar, Germany). Any immunolabeled vessel, clearly separate from an adjacent one 
and either totally inside the graticule or touching its top or left border, was counted as a microvessel.105 
To assess intraobserver reproducibility, hot spots were reidentified in a masked fashion six months 
later from a subset of 31 slides (25%) immunostained with mAb QBEND/10, chosen on the basis of a 
random number table. 
 
4.3.4 Tumor-infiltrating macrophages 
 
In preliminary experiments, mAb 3A5 immunolabeled dendritic macrophages less effectively than 
mAb PG-M1, in line with a previous study.218 Mab KP1 to the CD68 epitope cross-reacted with 
cytoplasm of some uveal melanomas, but such cross-reactivity was not found with mAb PG-M1. This 
mAb has shown a more restricted reactivity with the highly glycosylated and antigenically 
heterogeneous CD68 molecule than other mAbs to CD68.216 Based on the facts above, PG-M1 to the 
CD68 epitope was chosen as default antibody of the study.   
 
Macrophages were counted semiquantitatively in two ways based on standard photographs (Fig. 1 in 
III). The number of CD68-immunopositive cells was graded as few, moderate numbers, and many. The 
predominant morphological type of cells immunoreactive with mAb PG-M1 was graded as follows. 
Two groups consisted of tumors in which the majority (75% or more) of immunopositive cells were 
either dendritic or round in type. The third group consisted of tumors in which neither dendritic nor 
round CD68-immunopositive cells clearly predominated, or the morphology of immunopositive cells 
was intermediate between the dendritic and round type. Confluent immunopositive cells in necrotic 
areas did not influence the grading. 
 
 
4.3.5 Ezrin immunoreactivity 
 
Ezrin immunoreactivity was graded semiquantitatively into three groups under a double-headed 
microscope by two investigators according to predefined criteria: negative (no or only few 
convincingly immunopositive tumor cells), positive (faint to moderate, easily recognizable positive 
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granular immunoreaction in the majority of tumor cells), and strongly positive (stronger than average 
granular immunoreaction in the majority of tumor cells)(Fig. 1 in IV). The retina and choroid showed 
variable background, and neoplastic cells were graded immunopositive only if the reaction intensity 
was indisputably stronger than the background. 
 
4.4 STATISTICAL ANALYSES 
 
4.4.1 General guidelines 
 
Descriptive statistics for normally distributed variables were given as mean and standard deviation and 
for other variables as median and range.220 Confidence intervals (95%) were calculated for proportions. 
In the design phase of each study it was decided how variables will be divided into categories for 
hypothesis testing.  P values less than 0.05 were taken as statistically significant and warranted the 
rejection of the null hypothesis. Multiple comparisons were adjusted for by the Bonferroni 
correction.220 
 
4.4.2 Power and sample size calculation 
 
Calculation of the number of patients needed to prove a clinically significant difference in survival was 
done by simulation using a program that is available free of charge from Michael Borestein, New 
York, U.S.A.221 The simulation was based on published survival statistics whenever such were 
available. In case of microvascular loops and networks, the simulation was based on Folberg's cohort 
study, in which 10-year cumulative melanoma-specific survival differed by 0.37 between patients with 
and without networks.102 The corresponding difference for loops and no loops was 0.36.102 The 
simulation indicated that a sample of 150 patients is needed to prove or disapprove of 0.20 difference 
in survival. The power of the study was 0.9 (for a two-tailed alpha of 0.05). 
 
The calculation of the number of patients needed to prove a statistically significant difference between 
MVD and survival was based on the analysis of MVD by Foss and co-workers.105 In their study the 
survival of patients with a lower and higher MVD than the median was 0.70 and 0.35, respectively, 
with a 0.35 difference in survival.105 To detect such a difference with a power of 0.90 (given a two-
sided alpha of 0.05), the simulation gave a minimum total sample size of 82 patients, divided equally 
between the two arms. 
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Because no previous studies either on macrophage infiltration or ezrin immunoreactivity and survival 
in uveal melanoma were available, formal sample size calculation for Kaplan-Meier analysis was not 
feasible. Power analysis by simulation indicated that the study of macrophages and ezrin had 80% 
power to detect a 0.25 difference and 95% power to detect a 0.32 difference in 20-year survival. 
 
4.4.3 Group comparisons 
 
4.4.3.1 Interrelationships between variables 
 
For statistical comparisons continuous data, such as LBD and MVD (globally highest microvessel 
count obtained with mAb QBEND/10 to CD34) were categorized: the former in three categories (small 
≤10 mm, medium-sized 10-15 mm, and large >15 mm) and the latter was divided in quartiles (
microvessels, 25-40 microvessels, 41-57 microvessels, and 	
		
into two categories according to the presence or absence of epithelioid cells (spindle, nonspindle) and 
tumor locations according to the presence or absence of ciliary body involvement. Degree of 
pigmentation was analyzed as an ordered three-category variable (amelanotic to weak, moderate, and 
strong pigmentation). Microvascular loops and networks were analyzed as an ordered variable that 
considered networks to be an advanced stage of loops (no loops, loops without networks, networks). 
The number of macrophages was analyzed as an ordered (few, moderate, many CD68-immunopositive 
cells) and the predominant morphologic type of macrophages as an unordered three-category variable 
(dendritic, intermediate, round CD68-immunopositive cells). Immunoreactivity with mAb 3C12 to 
ezrin was primarily analyzed as an ordered three-category variable (negative, positive, strongly 
positive) and secondarily as a two-category variable (negative and positive).  
 
Fisher's exact and Pearson´s chi-square tests were used to compare proportions in 2 x 2 and larger 
unordered contingency tables, respectively. Kruskal-Wallis and Jonckheere-Terpstra tests were used to 
compare proportions in singly ordered and in doubly ordered contingency tables, respectively. 
McNemar’s test was used to compare paired 2 x 2 tables. Contingency tables were analyzed and exact 
probability distributions were computed with StatXact-3 (Cytel Software, Cambridge, MA). 
 
Scattergrams of MVD and LBD against other variables were plotted. The nonparametric Mann-
Whitney U test that does not require Normal distribution was used to analyze continuous variables 
between two independent groups, and the Wilcoxon rank-sum test was used to compare two paired 
samples of continuous data.  
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4.4.3.2 Inter- and intraobserver agreement 
 
Weighted kappa statistic was used to estimate chance-corrected interobserver agreement in 
identification of microvascular loops and networks, and in grading of the macrophages and ezrin 
immunoreactivity.220 Moreover, the number of disagreements, and whether they were one or two-
category disagreements, were recorded. Agreement between microvessel counts obtained from sections 
labeled with different antibodies and intraobserver reproducibility was assessed by plotting the 
difference between the two counts against their mean, and by calculating the mean difference with 
95% limits of agreement.220  
 
4.4.4 Survival analyses 
 
4.4.4.1 Kaplan-Meier method 
 
The survival analyses were performed with the BMDP PC-90 Statistical Software package (BMDP 
Statistical Software, Cork, Ireland) and with the SPSS for Windows 9.0.1 (SPSS Inc., Chicago, IL). 
Survival analysis was based on Kaplan-Meier product-limit method, and melanoma-specific survival 
was compared with the Mantel-Cox test that gives equal weight to the entire survival curve.220,222 
Trend test was used if the categories analyzed were ordered.222 Patients judged to die of other causes 
were censored at their time of death. To guard against the possibility that they were more or less likely 
to have progression than other patients, all-cause mortality was also analyzed. Because all-cause 
mortality in long- follow-up will always approach 100%, the Breslow test was the primary statistic in 
comparing all-cause mortality.222  
 
4.4.4.2 Cox multiple hazard regression  
 
Cox proportional hazards regression was used to adjust the survival for the effect of previously 
identified independent predictors of prognosis. LBD and MVD were analyzed as continuous variables. 
MVD was square root-transformed to normalize its distribution.105 In the first study, a best-fit model 
was obtained by forward stepwise regression.223 In subsequent studies, the effect of new variables was 
adjusted for variables already present in the main model. The assumption of proportional hazards was 
assessed by adding each covariate by log-time interaction to the model and assessing the significance 
of the product term using the partial likelihood ratio test.223 Variables that did not fulfil the assumption 
of proportional hazards were handled as stratification variables.222  
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5. RESULTS AND DISCUSSION 
  
5.1 DATA INTEGRITY 
 
5.1.1 Confirmation of histopathological diagnosis 
   
A panel of antibodies with a known immunostaining profile was used to recognize melanomas from 
carcinomas: mAbs HMB-45 to immature melanosomes that labels more than 90% of primary and 
metastatic uveal melanomas,214,224 mAb CY-90 to cytokeratin (CK) 18 that is expressed e.g. by adeno-
carcinomas, but can also be found in a minority of cells in uveal melanomas, mAb Vim 3B4 to 
vimentin that labels uveal melanomas but may also label cells in some carcinomas, and mAb E29 to 
EMA produced by adenocarcinomas but not by melanomas.142 An amelanotic tumor was accepted as a 
melanoma if it showed matching histopathological features and a positive immunostaining reaction for 
HMB-45, vimentin, or both, but not for CK 18 and EMA, and as a carcinoma when the antigenic 
profile was the opposite.142  
 
Immunolabeling with mAb HMB-45 against premature melanosomes was seen in 35 of 36 amelanotic 
primary melanomas (97%, 95% CI = 85-100). The only negative one reacted for vimentin with mAb 
Vim 3B4, and it did not react with mAb CY-90 to CK 18. When melanin pigment was visible in 
cytoplasm of tumor cells, melanoma diagnosis of primary tumor was accepted without the use of IHC. 
 
The autopsy rate of 32% in present study is much higher than the rate of 6% in COMS, but the portion 
of patients who had histologically proven melanoma metastasis was comparable, 84% in present vs. 
79% in COMS.91 Of the 59 studied metastatic tumors, the original diagnosis was found to be incorrect 
in 5 (8%, 95% CI = 3-19). Three amelanotic metastases from uveal melanoma had been misdiagnosed 
as metastatic carcinoma. Conversely, a hepatic metastasis from a carcinoma had been misdiagnosed as 
metastatic melanoma. Finally, one biopsy had been read as metastatic mucocellular carcinoma, but 
specimens taken later at autopsy, as metastatic uveal melanoma. Antigenic profiles of misdiagnosed 
tumors are presented in Table 5. Of the 50 true metastases from uveal melanoma, 46 (92%, 95% CI = 
80-98) were immunoreactive with mAb HMB-45.  
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Table 5.  Antigenic profile of histopathologically misdiagnosed metastatic tumors 
----------------------------------------------------------------------------------------------------------------------------- 
 Antibodies  
    ---------------------------------------------------- 
Site Misdiagnosis HMB-45 Vim3B4 CY-90 E29  Correct Diagnosis 
----------------------------------------------------------------------------------------------------------------------------- 
Liver Carcinoma + + - - Melanoma 
Liver Carcinoma + + - - Melanoma 
Liver Carcinoma + + - - Melanoma 
Liver Melanoma - - + + Carcinoma 
Liver Melanoma - - + + Carcinoma 
------------------------------------------------------------------------------------------------------------------------ 
A misdiagnosis frequency of 8% among histopathologically diagnosed metastases before routine IHC 
is significant. Previously, one metastatic carcinoma incorrectly diagnosed as amelanotic malignant 
uveal melanoma was identified among the subset of primary tumors included in the present study.142 
Consequently, even without IHC, the rate of histopathologic misdiagnosis of primary uveal melanoma 
is very low, approximately 1/168 (0.6%, 95% CI = 0-3).  
 
The results suggest a bias in retrospective studies based on cancer registry data. Histopathological 
diagnosis should be confirmed by immunohistochemistry whenever there is a possibility that 
amelanotic tumor might be melanoma, because an amelanotic epithelioid cell melanoma may be easily 
confused with adenocarcinoma and vice versa.142 No single specific antibody for uveal melanoma 
exists. Thus a panel of antibodies that have a different staining pattern in melanoma and carcinoma 
provides the most reliable differentiation of these two entities.142 
 
5.1.2 Pattern of metastatic disease 
 
Of 80 patients who died of metastatic uveal melanoma, clinical charts were available from 77 (96%) 
patients to record metastatic disease in detail. Metastatic disease involved liver in all patients except 
one who died of brain metastasis. Other common metastatic sites were lung, skin, abdominal lymph 
nodes, and bone (Table 6). Surprisingly, among the 27 autopsied patients with disseminated uveal 
melanoma, 5 (19%) were autopsied without a suspicion of metastatic cancer. The number of known 
metastases increased under autopsy (Table 6) that was line with a recent report of COMS.91 We 
previously stated that patients have not been selected to the autopsy based on extent of dissemination 
or presence of symptoms.90 Case reports of “unconventional” sites of metastatic melanoma have 
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suggested that widespread melanoma is clinically underestimated unless autopsy has not been 
performed.35,90,91,225,226 
 
Careful review of clinical charts and confirmation of histopathological diagnosis are warranted. 
Although the underlying cause of death of patients is available from registries in most Western 
countries, these registries are known to contain inaccuracies.227,228 Inaccuracies seem to concern 
especially ocular melanoma, because even one a half of the deaths due to ocular melanoma can be 
missed if only death certificates are used.227 
 
Table 6. Sites and frequencies of metastases on 77 of 80 patients who died of disseminated uveal 
melanoma 
----------------------------------------------------------------------------------------------------------------------------- 
        Autopsied  Not Autopsied  All 
 ------------------------------------------------ --------------------- ------------------- 
 Prior to autopsy  At Autopsy Clinical Total 
 N=27 N=27 N=50 N=77 
 ------------------------------------------------------------------------------------------------------- 
Sites N  (%)  95% CI N  (%)  95% CI N (%) 95% CI N (%)    95% CI 
 ---------------------------------------------------------------------------------------------------------------------------- 
Liver 19 (73) 50-86 26 (96) 81-100 50 (100) 89-100 76 (99) 93-100 
Lung   2   (7)   1-24   8 (30) 14-50 13 (26) 15-40 21 (27) 18-39 
Skin   2   (7)   1-24   2   (7)   1-24   8 (16)   7-29 10 (13)   6-23 
Lymph node   2   (7)   1-24   9 (33) 17-54   1   (2)   0-10   9 (12)   6-21 
Bone   0   (-)     -   1   (4)   0-19   8 (16)   7-29   9 (12)   6-21 
Heart   0   (-)     -   5 (19)   6-38   0   (-)     -   5   (7)   2-15 
Adrenal gland   0   (-)     -   3 (11)   2-29   0   (-)     -   3   (4)   1-11 
Pancreas   1   (4)   0-19   7 (26) 11-46   0   (-)     -   7   (9)   4-18 
Thyroid gland   0   (-)     -   2   (7)   1-24   0   (-)     -   2   (3)   0-9 
Ventricle   0   (-)     -   1   (4)   0-19   1   (2)   0-10   2   (3)   0-9 
Brain   1   (4)     0-19   3 (11)   2-29   2   (4)   1-14   5   (7)   2-15 
Spleen   0   (-)  -   2   (7)   1-24   2   (4)   1-14   4   (5)   1-13 
Kidney   0   (-)     -   3 (11)   2-29   1   (2) 0-10   4   (5) 1-13 
Bladder   0   (-)  - 2   (7)   1-24 0   (-)   -   2   (3)    0-9 
------------------------------------------------------------------------------------------------------------------------- 
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5.2 CLINICAL AND HISTOPATHOLOGICAL TUMOR CHARACTERISTICS  
 
5.2.1 General characteristics 
 
Of the 167 patients 76 were (46%) men and 91 (54%) were women. The mean age at removal of the 
eye was 58 years (median, 61 years; range, 13-95 years). The tumor was entirely choroidal in 126 
(75%) eyes and ciliochoroidal in 40 (24%) eyes. Of 40 ciliochoroidal tumors, 4 (10%) involved only 
the ciliary body by histopathology, which was too small a group for statistical analysis. The mean LBD 
was 13 mm (median, 13 mm; range, 6-25 mm) and the mean height was 8 mm (median, 7 mm; range 
2-20 mm) and the series thus represented melanomas of all sizes. According to LBD, 44 (27%) tumors 
were classified as small (≤10 mm), 69 (43%) as medium-sized (>10-15 mm), and 49 (30%) as large 
(>15 mm). The tumor extended extraocularly in 18 cases (11%). Bruch’s membrane was ruptured in 75 
(48%) cases. The tumor consisted of spindle cells in 86 (64%) eyes, and 48 (36%) tumors contained 
epithelioid cells and were classified to be nonspindle type. No retinal detachment (RD) was present in 
35 eyes (25%), subretinal fluid around the tumor was found in 23 (16%) eyes, RD involved 1-2 
quadrants in 61 (43%) and 3-4 quadrants in 23 (16%) eyes. Tumor pigmentation was weak in 38 
tumors (27%), moderate in 71 tumors (49%), and heavy in 35 (24%) tumors.        
 
5.2.2 Microvascular loops and networks of primary tumors 
 
At least one complete loop was detected in 80 tumors (60%, 95% CI = 51-68) and networks in 47 
tumors (35%, 95% CI = 27-44). Networks were found somewhat more frequently in Folberg’s series 
(45%; 95% CI = 49-52), and the frequency of networks was smaller in Foss' inconsecutive series 
(25%; 95% CI = 17-34).102,148 The interpretation of a “loop” or “microvessel” in general may have 
varied between these groups, which may explain part of the difference in frequencies.102,148 Foss and 
his group doubted the origin of microvascular patterns and claimed them to be fibrovascular tissue.148 
They were not able to demonstrate patterns well with PAS and a polyclonal antibody to FVIII-related 
antigen, and they concluded that microvascular patterns cannot be of microvascular origin.148 
McLean’s group detected loops in only 157 of 496 tumors (32%, 95% CI = 28-36) but they used 
archival unbleached PAS slides that had been counterstained, which may obscure part of the 
microvascular patterns.141 Likely explanations for varied frequencies are inclusion criteria and rates. 
Whereas 80% of patients were included in the present study, which can be considered a high rate in a 
retrospective study, the inclusion rate in the other studies mentioned ranged from a low rate of 11% to 
a medium rate of 55%.102,141 Because the presence of loops and networks correlated with poor 
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prognosis, it is unlikely that the lower frequencies of loops and networks in Foss' study were due to 
random chance, because the series was enriched with tumors that have metastasized.148 Random 
chance might apply to a small Japanese series that found loops and networks in 31% (95 % CI = 11-
59) and 25% (95% CI = 7-52) of tumors, respectively.149 
 
Interobserver agreement was good in the present study, the kappa statistic was 0.70 (95% CI = 0.57-
0.82) for loops and 0.67 (95% CI = 0.53-0.80) for networks. Folberg and colleagues reached similar 
interobserver agreements in classifying loops and networks (kappa 0.67 and 0.59, respectively) 
indicating that assessment of microvascular loops and networks is reproducible across laboratories.102  
 
The analysis of the distribution of prognostically significant microvascular patterns (parallel vessels 
with cross-linking and networks) across multiple levels of tumor showed that a single section taken 
from the central part of a tumor contained the pattern if it was found in the tumor.229 In a few 
specimens some microvascular patterns disappeared from sections from the edge of tumor although 
they were present at other levels.229 On the other hand, a study based on a single slide from the tumor 
suggested that parallel with cross-links and networks patterns have a preferential location in the tumor 
periphery.230 The findings suggest that the inclusion criterion of requiring over 50% remaining tumor 
likely ensured that the sections were representative for detection of loops and networks.  
 
5.2.3 Microvascular loops and networks of metastatic tumors 
 
Of 33 metastatic specimens studied, at least one microvascular loop was detected in 27 specimens 
(82%, 95% CI = 65-93). The overall frequency of loops was comparable in metastases and their 
corresponding primaries (P  = 1.0, McNemar’s test). The presence and absence of microvascular loops 
differed in 10 patients (30%, 95% CI = 16-49) in their primary tumor and metastatic sites: five times 
loops were absent from the primary tumor but existed in metastasis, and five times loops were present 
in the primary tumor but were absent from the metastatic tumor. In one case (3%, 95% CI = 0-16) the 
loop pattern, and thus also the network pattern, were absent from both the primary and the metastatic 
tumor. 
 
Networks were detected in 18 metastatic specimens (55%, 95% CI = 36-72). The status of 
microvascular networks was different in 14 (42%, 95% CI 26-61) corresponding primary and 
metastatic tumors. In 6 patients (43%) networks were absent from primary tumor but they were found 
from metastatic specimen, and 8 patients (57%) had no networks in metastasis but had them in the 
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primary tumor. Presence of microvascular networks did not differ statistically between primary and 
metastatic tumors (P = .79, McNemar’s test). 
 
Previously microvascular patterns have been analyzed in hepatic metastases of five uveal melanoma 
patients and each of them contained microvascular networks (100%, 95% CI = 48-100).231 The present 
study does not suggest that an enrichment of microvascular loops and networks would occur when 
metastasis develops, and the confidence intervals of the two studies overlap. Neither was the sample 
large enough to confirm small differences in frequencies statistically. Moreover, studying only one 
section of a single metastasis does not exclude the possibility that microvascular loops and networks 
might be present elsewhere in the metastasis or in other metastases. The differences in microvascular 
loops and networks between primary and metastatic tumors, when present, might reflect true variation 
in tumor characteristics between primary and metastatic sites, e.g. in the propensity of hepatic 
metastases to spread to tertiary sites. 
 
Microvessels in metastases have clinical importance, because new therapeutic drugs targeted to blood 
vessels, such as angiogenesis inhibitors, have shown effect on controlling tumor growth in vitro.232 
Interestingly, drugs impacted, however, differently microvessels formed by tumor cells than vessels 
formed by endothelial cells.233 The use of inhibitors of vasculogenic mimicry, such as inhibitors of 
epithelial cell kinase (e.g. Eck/EphA2), may offer novel therapeutic applications.154  
 
5.2.4 Microvascular density of primary tumors 
 
The median MVD based on the globally highest count was 40 vessels/0.313mm2 (range, 5-121), and 
the median MVD based on the three highest counts averaged was 33 vessels/0.313mm2 (range, 5-113), 
as analyzed with antibodies to the CD34 epitope. The corresponding MVDs obtained with antibodies 
to FVIII-RAg were 33 (range, 6-102) and 27 (range, 4-84) vessels/0.313 mm2, respectively. Strong 
agreement existed between the mean of the three highest counts and the globally highest vessel count, 
and no obvious advantage was obtained from counting three separate areas.  
 
Foss and associates used also FVIII-RAg and they obtained a median MVD of 40 microvessels, 
counted from a of 0.25 mm2 single globally highest area of vascularization.105 In two other data sets, 
however, MVD was reported to be much lower than in the present and Foss’ studies.166,167 In a case-
control study of 63 tumors, two hot spots were counted from predetermined areas of tumor and the 
median MVD ranged from 5.7 to 11.4 vessels per counted area.166 In a follow-up study of 40 uveal 
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melanomas, MVD was determined from five randomly chosen areas and the mean MVD ranged from 
1 to 12.5 vessels per 0.216mm2.167 
 
The main difference between these studies on MVD, and the most likely reason for different results, is 
the strategy of selecting areas to be counted. In the present study and in the series of Foss,105 the 
analysis was based on the globally highest MVD (“hot spot”). Whereas, counting vessels from 
predetermined and random areas in the two other studies is likely to have had impact on MVDs, 
probably making them smaller and less variable than using the hot spot counting. The area to be 
counted should not be too small or too large to prevent exaggerating or dilution of the hot spot.234 The 
method of visualizing microvessels also varied. Whereas our preferred marker was CD34 epitope, 
Lane used Ulex europaeus agglutinin I and the other two groups used FVIII-RAg.105,166,167 The latter 
markers are thought to be less sensitive than the CD34 epitope, especially as regards to microvessels 
seen in malignant tumors, and weak or incomplete staining has been reported also in uveal 
melanoma.2,235  
 
Intraobserver reproducibility in assessing MVD with antibodies to the CD34 epitope, as evaluated by 
the difference between initial and repeated square root transformed counts from reidentified hot spots, 
was 0.28 units less (95% CI = 0.07-0.50) on recounting based on the globally highest count, and 0.25 
units less (95% CI = 0.02-0.48) on recounting based on the three highest counts averaged, 
corresponding to 3 and 1.7 vessels less per recounted area. The intraobserver reproducibility was 
regarded satisfactory.220 Other investigators have reported good intraobserver and interobserver 
reproducibility for repeated counts, especially when based on hot spots, but the data were usually 
categorized and analyzed by kappa statistic. 160 
 
Because sections labeled with antibodies to the CD34 epitope were easier to read and thus more 
convenient to count than those labeled for FVIII-Rag (Fig. 1, A and B in II), and also yielded higher 
counts, it would seem reasonable to use the globally highest count obtained with antibodies to the 
CD34 epitope in further studies of uveal melanoma. The CD34 antigen is a cell-membrane associated 
glycoprotein that is frequently found on pluripotent hematopoietic progenitors, vascular endothelial 
cells, and embryonic fibroblasts.236 The CD34 antigen has a large number of different glycosylation-
dependent epitopes and mAb QBEND/10 to the CD34 recognizes its class II epitopes that are sensitive 
to enzymatic cleavage of the glycoprotease.236     
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It must be realized that MVD as defined here is more of a rough index of relative densest 
vascularization in the hot spots rather than an exact measure of the number of microvessels present. It 
is also possible that not all microvessels are immunolabeled with above antibodies, and that not all 
positive immunoreaction is restricted to endothelial cells.152  
 
5.2.5 Microvascular density of metastatic tumors 
 
MVD in uveal melanoma metastases has not previously been reported. The mean MVD in metastatic 
specimens was 52 immunopositive vessels/0.313mm2 (range 18-91 vessels) as obtained with mAb 
QBEND/10 to CD34 epitope. MVD tended to be higher and the range of variation smaller in 
metastatic tumors than in the corresponding primary tumors (P = .071, Wilcoxon signed ranks test), 
but overlapping was significant (Fig. 3A). On contrary to the primary tumors, MVD was not higher in 
samples that contain microvascular loops or networks (Fig 3B; P = .25, Kruskal-Wallis test). 
 
The present series of 33 patients is one of the largest series of uveal melanoma in which corresponding 
primary and metastatic samples have been studied. Nevertheless, the small number of patients makes it 
impossible to detect anything but a large difference as statistically significant. 
 
Figure 3. Scattergrams of MVD in metastases versus corresponding primary tumors and the presence 
of microvascular loops and networks (bars indicate median values) 
0 25 50 75 100 125
0
25
50
75
100
125
A MVD of Primary tumors
M
VD
 
o
f M
et
as
ta
se
s
No Loops Loops only Networks
0
25
50
75
100
B
M
VD
 
o
f M
et
as
ta
se
s
 Results and Discussion 
__________________________________________________________________________________ 
 50   
5.2.6 Tumor-infiltrating macrophages 
 
The number of CD68-immunopositive cells was semiquantitatively graded as few in 24 tumors (17%; 
95% CI = 11-25), moderate in 71 tumors (51%; 95% CI = 43-60), and many in 44 tumors (32%; 95% 
= CI 24-40). The predominant morphologic type of infiltrating cells was graded as dendritic type in 30 
tumors (22%; 95% CI = 15-29), intermediate in 82 tumors (59%; 95% CI = 50-67), and round in 27 
tumors (19%; 95% CI = 13-27). The interobserver agreement (weighted kappa) was 0.77 (95% CI = 
0.69-0.85) for grading the number and 0.60 (95% CI = 0.49-0.71) for grading the type of CD68-
immunopositive cells. These kappa values were considered moderate to good. 
 
Even though it has long been recognized that uveal melanomas contain macrophages, especially 
melanophages, this type of tumor-infiltrating cell has not been addressed widely in literature.115 In the 
ongoing Collaborative Ocular Melanoma Study (COMS), 1354 of 1526 (89%) enucleated melanomas 
had “none to minimal” or “scattered single small clumps”, and 172 tumors (11%) had “scattered single 
and larger aggregates" of macrophages, as judged by light microscopy.111 In current analysis, 
especially round CD68-positive macrophages could amount to almost one quarter of the tumor cross-
sectional area in nonnecrotic regions (>650 cells/mm2) and the number of dendritic CD68 positive cells 
could be equivalent in other tumors. Tobal and associates have also noted a dense infiltration of CD68-
positive macrophages (range 1200-1400 cells/mm2) in 16 uveal melanomas.110 Taken together, it 
seems evident that light microscopic examination without labeling macrophages by 
immunohistochemistry and without bleaching of melanin underestimates the number of macrophages 
(CD68+ cells).  
 
The target antigen of antibodies to CD68, is an intracytoplasmic 110 kD glycoprotein that resides in 
lysosomal granules and is expressed by macrophages.216,217 During differentiation of monocytes into 
macrophages the expression of CD68 increases markedly,237 but the function of the CD68 epitope has 
remained unknown both in macrophages and in other cell types. The role of macrophages is currently 
completely open in uveal melanoma. 
 
5.2.7 Ezrin immunoreactivity 
 
A granular, diffuse intracytoplasmic immunoreaction that frequently was concentrated focally along 
the cell surface was obtained with mAb 3C12 in uveal melanoma cells. The two investigators agreed 
on the grade of ezrin immunoreactivity in 82 of the 130 specimens (63%, 95 % CI = 54-71). After 
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consensus, 47 (36%, 95% CI = 28-45%) melanomas were classified as negative, 74 (57%, 95% CI = 
48-66) as positive, and 9 (7%, 95% CI = 3-13) as strongly positive for ezrin. Some discrepancies were 
due to the presence of large numbers of immunopositive lymphocytes. A two-category discrepancy 
occurred once. The interobserver agreement (weighted kappa) was considered moderate and amounted 
to 0.50 (95% CI = 0.36-0.63). 
 
The labeling intensity ranged from negative to strongly positive. When positive, the immunoreaction 
tended to be homogeneous throughout the tumor. However, in 4 of the 130 melanomas (3 %, 95% CI = 
1-8) areas of weakly and strongly immunopositive tumor cells were found adjacent to each other. 
Adjacent sections immunostained with mAb PG-M1 and KP1 suggested that putative macrophages 
were typically not labeled by mAb 3C12. 
 
 
5.2.8 Interrelationships between prognostic indicators 
  
5.2.8.1 Microvascular loops and networks 
  
Tumors with nonspindle cells contained more often microvascular loops and networks, analyzed as a 
combined variable (no loops, loops without networks, and networks), than spindle cells melanomas (P 
= .003, Kruskal-Wallis test, Table 7). The association between microvascular loops and networks and 
epithelioid cell type is in line with the results of Folberg and coworkers.102 Moreover, they found that 
epithelioid melanomas contained more often parallel, arcs, parallel with cross-linking, and arcs with 
branching patterns than spindle cell tumors.102 Microvascular loops and networks tended to be more 
frequent in tumors with increasing LBD (P = .088, Jonckheere-Terpstra test). Microvascular loops 
were more common in tumors that involved the ciliary body (P = .040, Fisher's exact test), but such 
association was not observed in distribution of networks (P = 1.0, Fisher's exact test). Two other 
groups, however, have reported that ciliary body melanomas contained more often microvascular loops 
and networks than choroidal melanomas.106,123 This discrepancy may result from small and biased 
sample in case of the recent study106 or from differences in identification of microvascular loops and 
networks. One possible explanation might be misidentification of ciliary muscle bundles as networks 
as they can resemble networks in PAS staining (Fig. 1,G and H in I). The degree of tumor 
pigmentation, the number and type of tumor-infiltrating macrophages, and the ezrin immunoreactivity 
were not associated with the presence of microvascular loops and networks. 
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Interestingly, in the present study MVD was higher in tumors that contained microvascular loops and 
networks (P = .001, Jonckheere-Terpstra test), although globally highest microvessel count tended to 
be found from areas not involved by microvascular loops and networks. Moreover, no immunopositive 
microvessels were found inside the loops and networks. Foss and associates reported a higher MVD in 
tumors with parallel, parallel with cross-links, arcs, arcs with branches, and networks than in tumors 
that lacked these prognostically significant microvascular patterns.148 Surprisingly, the MVD was 
lower in tumors with loops than in tumors that lacked loops.148 They did not speculate on this finding, 
but addressed an incomplete immunostaining of microvascular patterns with FVIII-RAg and 
questioned the microvessel nature of microvascular patterns.148 
 
5.2.8.2 Microvascular density 
  
The MVD was statistically significantly higher in melanomas that contained non-spindle cells (P = 
.011, Kruskal-Wallis test). Moreover, large tumors had higher MVD (P = .006, Jonckheere-Terpstra 
test), consistent with the study of Foss and coworkers (Table 7).105 Substantial overlap was, however, 
observed especially as regards tumor size (Fig. 3, C and D in II). The connection between large tumor 
size and high microvascular density is true for other tumors as well, and may signify that tumor 
progression and growth are dependent on rich tumor circulation.159-161 It seems also possible that a 
biologically significant association may exist between epithelioid cell type and specific 
microcirculation features in uveal melanoma. The biological significance of the observed statistical 
association between immunoreactivity for ezrin and high MVD remains unsolved (P = .004, Kruskal-
Wallis test), as well as the relationship between high MVD and heavy tumor pigmentation (P = .013, 
Jonckheere-Terpstra test). MVD was not associated with ciliary body involvement, extraocular 
extension, sex, or age of the patient. 
  
5.2.8.3 Tumor-infiltrating macrophages 
  
Melanomas with large LBD (P = .031, Jonkheere-Terpstra test), high MVD, heavy pigmentation (P = 
.001, Jonckheere-Terpstra test), and epithelioid cells (P = .025, Kruskal-Wallis test) had statistically 
significantly more macrophages than small and weakly pigmented melanomas and melanomas without 
epithelioid cells, respectively, but overlap between categories was notable (Fig. 2, A and B in III) 
(Table 7). In addition, females had statistically significantly more tumor-infiltrating macrophages than 
males (P = .010, Kruskal-Wallis test). 
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No association between the predominant type of CD68-immunopositive macrophages and LBD, the 
presence of epithelioid cells, MVD, and gender was observed. Weakly pigmented melanomas 
contained more often dendritic than round type of macrophages, whereas the reverse was true of 
heavily pigmented tumors (P = .001, Kruskal-Wallis test). The number and type of macrophages were 
interrelated (P = .005, Kruskal-Wallis test). When the number was small, the dendritic type 
predominated over the round type, and vice versa. The tumor pigmentation may have impact on 
morphology of tumor-infiltrating macrophages, but whether it has also impact on their function is 
unknown.  
 
Neither the number nor the predominant type of immunopositive cells was statistically significantly 
associated with involvement of the ciliary body, presence of extraocular extension, and presence of 
over 50% necrosis. Ciliary body melanomas have, however, been reported to contain more 
melanophages than tumors confined to choroid, but the number of melanophages was assessed without 
IHC.111 
  
5.2.8.4 Ezrin immunoreactivity 
  
The presence of immunoreactivity with mAb 3C12 was not statistically significantly associated with 
gender and  LBD (Table 7). In contrast, melanomas with high number of tumor-infiltrating 
macrophages (P = .0006, Kruskal-Wallis test) were statistically significantly more often labeled with 
mAb 3C12 to ezrin than tumors with low number of tumor-infiltrating macrophages (Table 7). 
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5.3 MELANOMA-SPECIFIC AND ALL-CAUSE MORTALITY 
 
5.3.1 Overall mortality 
 
At the end of the follow-up time (median 22 years, range 18-26 years), 37 of 167 patients (22%) were 
alive without evidence of metastatic melanoma and 130 (78%) patients had died. Of 130 deaths, 80 
(62%) were due to metastatic uveal melanoma, 9 (7%) were caused by carcinomas, and 41 (31%) were 
other than tumor deaths. The follow-up time of 22 years was sufficiently long to capture total mortality 
as completely as possible, and the present series is representative of the entire population of patients 
with uveal melanoma.  
 
The crude melanoma-specific mortality was 0.58 at the end of the median follow-up time of 22 years 
(Fig. 4A), which is in line with reports based on unselected series of uveal melanoma patients with 
long follow-up time.23,25,130 The cumulative melanoma-specific mortality was highest during the first 
three years from enucleation, also in line with a number of survival studies,93,122 being 0.30 at 5 years. 
Thereafter, melanoma-specific death rate remained relatively stable as long as follow-up continued, 
corresponding to 10-, 15- and 20-year mortalities of 0.41, 0.48, and 0.55 respectively (Fig. 4A).  
Metastatic melanoma remained the leading cause of death throughout the follow-up period. Based on 
this consecutive series, short follow-up times, such as 5 years, capture only about one half of all 
melanoma deaths. A statistically significant difference in melanoma-specific survival at 5-years of 
follow-up does not necessarily indicate that there will eventually be a significant difference in the long 
run.  
 
Early metastasis might only reflect a more advanced tumor or a more rapid progression of tumor, and it 
does not necessary mean that other patients would be safe from metastasis. Apparently most, if not all, 
uveal melanomas disseminate, but depending on patient’s age, competing diseases, and host factors, 
metastatic disease does not become clinically evident if the patient is censored because of unrelated 
death or short follow-up time. It is possible, but so far unexplored, that early melanoma deaths (e.g. 
<15 years from enucleation) and late melanoma deaths (e.g. >15 years from enucleation) may reflect 
differences in tumor biology and host response between patients. Consecutive and large representative 
series of uveal melanoma with extended follow-up time may shed light on the histopathological and 
host characteristics that determine progression to fatal disseminated disease within different time 
intervals.  
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Because patients with uveal melanoma are usually middle-aged or older, they are also at risk of dying 
of other illnesses than metastatic uveal melanoma.98 In reporting melanoma-specific mortality there is 
always a possibility that a patient with disseminated melanoma is censored from survival as being 
without an evidence of metastasis. Probably even performing a careful autopsy does not totally exclude 
micrometastatic disease, but as in present study, it may reveal clinically undetected metastases. To 
control for this source of bias, all-cause mortality is recommended as a secondary or even primary 
outcome measure in survival studies.98 The cumulative all-cause mortalities of current series were 0.37 
at 5 years, 0.56 at 10 years, 0.67 at 15 years, and 0.76 at 20 years (Fig. 4A). No difference in 
melanoma-specific mortality was observed between enrolled and excluded patients (Fig 4B; P = .49, 
Log-rank test). 
 
5.3.2 Prognostic significance of baseline characteristics 
 
Melanoma-specific survival was similar among both sexes (Fig. 4C; P = .54, Log-rank test), but older 
patients died more often of metastatic melanoma than younger patients (Fig. 4D; P = .006, Log-rank 
test for trend). Patients with extraocularly extended melanoma had 0.42 higher 10-year melanoma-
specific mortality than patients with entirely intraocular melanoma (Fig 4E; P < .0001, Log-rank test). 
Presence of large amount of necrosis (>50% of tumor section) increased melanoma mortality by 0.20 
(Fig 4F; P = .014, Log-rank test). 
 
The cumulative 10-year melanoma-specific mortality was 0.22 for small tumors (≤10 mm), 0.44 for 
medium-sized tumors (10-15 mm), and 0.60 for large tumors (>15 mm) by Kaplan-Meier analysis (Fig 
5A; P < .001 Log-rank test for trend). The prognostic significance of tumor size in uveal melanoma is 
well documented in many survival studies (Table 8).84,85,102,103,105,122,130,131 Large tumor size may 
indicate that the tumor has grown undetected for years inside the eye.93 Alternatively, it may have had 
a rapid growth rate as a sign of aggressive nature.238 In either case, a large tumor is more likely to be 
further advanced in tumor progression than a small one. Large tumors have sent micrometastases with 
a greater probability than small ones and micrometastases from large tumors may progress more often 
and more rapidly to clinically detectable metastases. 
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Figure 4. Kaplan-Meier curves of melanoma-specific survival. 
 
Patients with melanoma extending to the ciliary body had 0.36 units higher 10-year melanoma-specific 
mortality than patients with choroidal melanoma (Fig. 5B; P = .0002, Log-rank test). Anterior tumor 
location is an important clinical prognostic indicator and recent studies have shown that ciliary body  
involved melanomas tend to contain more often chromosomal abnormalities and microvascular 
networks,49,106,123-125 even though the present study failed to confirm the latter association. 
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The degree of tumor pigmentation was statistically significantly associated with melanoma-specific 
mortality (Fig 5C; P  = .0065, Log-rank test for trend). The 10-year cumulative probability of survival 
was 0.83 for weak, 0.44 for moderate, and 0.57 for heavy tumor pigmentation.  
 
Figure 5. Kaplan-Meier curves of melanoma-specific survival. LBD: small melanomas vs. medium-
sized melanomas vs. large melanomas (A), Tumor location: choroidal melanomas vs. melanomas 
involving the ciliary body (B), Tumor pigmentation: weakly pigmented vs. moderately pigmented vs. 
heavily pigmented melanomas (C), Cell type: spindle cell melanomas vs. nonspindle melanomas (D). 
 
Spindle cell tumors cause metastatic deaths, but at a lower rate than nonspindle tumors (Fig. 5D). The 
melanoma-specific mortality was higher after enucleation among patients with nonspindle cells than 
among patients with spindle tumors, and a survival difference of 0.35 to 0.38 remained after 5 years. 
The 10-year melanoma-specific mortalities were 0.26 for spindle cell and 0.64 for nonspindle tumors 
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(Fig. 5D; P <.001 Log-rank test). Nonspindle cells are obviously of more malignant phenotype.178,192 
They have a less cohesive growth pattern, and more DNA abnormalities than spindle cells.3,178,192 Cell 
type has been consistently associated with decreased survival in the vast majority of studies on uveal 
melanoma,86,102,122,130,132 but a few recent ones have failed to document such an association in 
multivariate analysis.105,194 Series based on histopathologic material collected during the era of eye-
conserving treatment options may represent more advanced cases of intraocular melanomas, which 
may affect the possibility to detect associations.194  
 
In a study based on present series of uveal melanoma patients, but not included in this thesis, suggested 
that increasing extent of exudative retinal detachment is associated with higher melanoma-specific 
mortality.239 The asscociation between RD and mortality disappered when survival was controlled for 
LBD and presence of microvascular loops and networks. 239  
 
5.3.3 Prognostic significance of microvascular loops and networks 
 
This study was not undertaken to explore all nine microvascular patterns to avoid statistical problems 
from multiple comparisons of variables that may not be independent from each other. Primary aim of 
the present study was to confirm or contradict the prognostic significance of microvascular loops and 
networks, which had previously been the most powerful and consistent prognostic indicators of the 
nine microvascular patterns (Table 8).102,104,141 This does not imply that the other seven patterns would 
not be clinically significant or interesting.240 Need for multiple comparisons between microvascular 
patterns and conventional prognostic indicators, as well as the limited number of metastatic deaths (n = 
80) also precluded a study of all nine patterns. 
 
The 10-year cumulative melanoma-specific mortality was 0.30 units higher for tumors with 
microvascular loops and 0.42 units higher for those with microvascular networks as compared to 
tumors without microvascular loops and networks (Fig. 6A; P  < .001, Log-rank test). A 10-year 
melanoma-specific survival difference of 0.35 (range 0.31-0.38) between patients with presence of 
loops or networks and patients who lack these patterns is established by several independent studies 
(Table 2).102,104,141 Results of multivariate analysis are more difficult to compare, because both the 
number of events and the number and type of other variables included in the model have a great impact 
on the statistics. Except for the study by Foss and co-workers,148 either loops or networks, entered as an 
independent prognostic indicator into a multivariate model adjusted for conventional prognostic 
indicators: cell type, largest basal tumor diameter, and ciliary body involvement (Table 2).102,104,141 
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No melanoma deaths have occurred so far among 16 of 37 patients with microvascular loops or 
networks who survived 16 years or more from enucleation in the present series (Fig. 6A). At same 
time, 6 of 26 (23%) patients who lacked microvascular loops and networks and had survived at least 
for 16 years from enucleation, have died of metastatic uveal melanoma (Fig. 6A). Such delayed 
melanoma deaths took place also within each quartile of MVD. As regards to LBD, other investigators 
have observed that its prognostic significance varies with the follow-up.241 These observations may 
indicate incorrect categorization or, perhaps more likely, as yet ill understood interplay with host and 
other tumor variables. 
 
Since eye-preserving treatment modalities are now preferred to enucleation, less histopathological 
material is routinely available for evaluation of indicators of metastatic disease. It is unclear how 
representative specimens taken by fine-needle biopsy for assessing microvascular patterns are, but the 
suction of tumor cells into syringe and smearing them on the slide probably change the architecture of 
microvessels making evaluation inconsistent, and also the sample volume would be small. The same 
also applies to MVD. In order to evaluate microvascular architecture from eyes that are not removed, 
indocyanine green angiography with confocal scanning laser ophthalmoscopy and high-frequency 
ultrasound have been evaluated as tools for visualising tumor vasculature in vivo.242-244 There is a clear 
demand for such methods, because identification of patients who are at high risk of dying of metastases 
is inaccurate if the evaluation is based on only traditional clinical prognostic factors, tumor size and 
tumor location. 
 
5.3.4 Prognostic significance of microvascular density 
 
As analyzed by the globally highest MVD obtained with antibodies to the CD34 epitope, the 10-year 
cumulative melanoma-specific mortality increased when the MVD increased, being 0.09, 0.29, 0.59, 
and 0.66 for the four quartiles from lowest to highest density (Fig. 6B; P <.0001 Log-rank test for 
trend). The above results are in line with an analysis recently conducted by Foss and co-workers,105 
who found a corresponding difference of 0.58 in 9-year probability of survival among 116 patients 
with choroidal and ciliary body melanoma using antibodies to FVIII-RAg. In both studies, the risk of 
death increased from quartile to quartile.105  
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Figure 6. Kaplan-Meier curves of melanoma-specific survival.  Microvascular patterns: melanomas 
without loops vs. melanomas with loops but without networks vs. melanomas with networks (A), MVD: 
globally highest microvessel count (B), Number and Type of tumor-infiltrating macrophages (C, D), 
Ezrin immunoreactivity: three-category (E) and two-category (F) classifications. 
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Two other studies on uveal melanoma have failed to document any relationship between survival and 
MVD.166,167 In addition to relatively small sample size, a modified methodology was used in assessing 
MVD, as already mentioned. Such negative studies have been published also from other cancers, but 
about three quarters of studies have shown an association between high MVD and tumor-specific 
survival, even in tumors such as breast cancer that also frequently spread via the lymphatic 
route.159,160,160,161 
 
5.3.5 Prognostic significance of tumor-infiltrating macrophages 
 
Melanoma-specific mortality was significantly associated with the number of CD68-immunopositive 
cells (Fig. 6C; P = .0012, Log-rank test for trend). The 10-year cumulative probability of survival was 
0.90 for few, 0.58 for moderate numbers, and 0.43 for many immunopositive cells. In contrast, the 
predominant type of CD68-immunopositive cells identified with mAb PG-M1 was not significantly 
associated with melanoma-specific mortality (Fig. 6D; P = .66, Log-rank test) 
 
The presence of a high number of macrophages in aggressive melanomas might either be an indication 
of a host response mounted against more malignant tumors or it might simply be indirect evidence of 
an aggressive tumor that has a high cell turnover rate and consequently a need for phagocytosing cells. 
Melanoma cells may modulate the infiltration of monocytes by secreting cytokines such as monocyte 
chemotactic protein-1.245   
 
5.3.6 Prognostic significance of ezrin immunoreactivity 
  
The 10-year cumulative melanoma-specific probability of survival was 0.84 for melanomas not 
immunoreactive with mAb 3C12, 0.43 for tumors that were immunoreactive, and 0.63 for tumors that 
were strongly immunoreactive (Fig. 6E; P = .018 Log-rank test for trend). Due to the small sample size 
of strongly ezrin immunoreactive tumors, strongly positive and positive tumors were combined as a 
secondary analysis and significant survival difference was observed as compared to ezrin 
immunonegative tumors (Fig. 6F; P = .0014, Log-rank test). 
 
The expression of ezrin in endometrial carcinoma, pancreatic carcinoma, and hemangioblastoma cell 
lines has suggested its role as a modulator of tumor cell morphology, migration, and invasion.219,246-248  
Recently, ezrin immunoreactivity with mAb 3C12 was associated with increasing malignancy of 
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astrocytic tumors.249 Evidence is lacking on functions of ezrin in uveal melanoma, but the study of 
invasive inconverted uveal melanoma cells indirectly suggests a role for ezrin in uveal melanoma: 
melanoma cells that expressed the transmembrane c-met receptor were highly rensponsive to the 
motogenic effects of HGF.168 C-met acts as a receptor of HGF and conducts the signal to intracellular 
ezrin which links the plasma membrane to the actin cytoskeleton.250,251 Of other tumors, co-expression 
of HGF and c-met is documented in endometrial carcinoma, in which c-met expression also 
contributed to shorter survival.252 Worth studying is whether uveal melanoma cells express c-met, 
whether c-met expression is increased in tumors with ezrin immunoreactivity, and whether c-met might 
be involved in liver-targeted metastasis. Ezrin might also modulate cell recognition by the immune 
system e.g. natural killer cells.253 
 
5.4 COX PROPORTIONAL HAZARD REGRESSION ANALYSES 
 
5.4.1 Univariate analysis 
 
Risk for metastatic disease increased with increasing tumor size: the risk was 1.12 times greater for 
each mm that exceeded the mean LBD of 13 mm by univariate Cox regression (Table 8). Similarly, 
each mm over the mean height of 7 mm meant 1.13 times greater risk for metastatic death.  The ciliary 
body involvement indicated 2.21 times higher risk for metastatic death (Table 8).   
 
Because microvascular loops and networks are closely interrelated, the statisticians of the Journal of 
the National Cancer Institute encouraged us to analyze them as a combined variable: no loops, loops 
without networks, and networks. By Cox analysis, the risk for metastatic death was 1.81 times higher if 
a patient had microvascular loops, and 3.3 times higher if he or she had networks as compared to a 
patient who lacked loops and networks. Hazard rate for MVD was 1.33 for each unit change in square 
root transformed vessel count (Table 8). Ezrin immunoreactivity indicated a 2.5-fold risk for metastatic 
death. The number of macrophages did not fulfil the proportional hazards assumption (Χ2 = 5.48; 1 df; 
P = .019, indicating that the risk changes over time, and the hazard is not proportional) and this 
variable was modelled by stratification. 
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5.4.2 Multivariate analysis 
 
The multivariate model was built step by step, basing every new model on the previously obtained best 
model. Variables that independently indicated prognosis in the final main model were: the presence of 
epithelioid cells (HR 1.84), large tumor size (HR 1.14 for each mm increase in tumor diameter), high 
MVD (HR 1.20 for each unit increase in square root transformed vessel count), presence of 
microvascular loops and networks (HR 1.35 for each change in category), and ezrin immunoreactivity 
(HR 1.71) (Table 9). The number of macrophages was modelled as a stratification variable and it 
improved the models statistically significantly (P < .001 Chi-squared test). 
 
Table 9.  Final multivariate Cox proportional hazards model stratified by the number of macrophages 
----------------------------------------------------------------------------------------------------------------------------- 
Variable Regression Likelihood P HR  (95% CI) 
  Coefficient (SE) Ratio 
----------------------------------------------------------------------------------------------------------------------------- 
Epithelioid cells†  0.612  (0.282)  4.7 .030 1.84  (1.06-3.21) 
Largest basal diameter  0.128  (0.040)  10.4 .0012 1.14   (1.05-1.23) 
Microvascular patterns*  0.304  (0.161)  3.6 .057 1.35  (0.99-1.86) 
Microvascular density§  0.179  (0.079)  5.1 .024 1.20  (1.02-1.40) 
Ezrin¶  0.536  (0.325)  2.9 .087 1.71  (0.90-3.23) 
----------------------------------------------------------------------------------------------------------------------------- 
* Categories: No loops = 0, Loops without networks = 1, Networks = 2 
Other symbols are given in Table 8 
 
5.4.3 Adjusted survival 
 
The melanoma-specific survival curves adjusted for other variables included in the final multivariate 
model were generated for LBD, cell type, microvascular loops and networks, MVD, and ezrin 
immunoreactivity. The 10-year melanoma-specific mortality increased (0.16 for small, 0.32 for 
medium-sized, and 0.45 for large) among large tumors even when survival was adjusted for the 
presence of epithelioid cells, microvascular loops and networks, MVD, and ezrin immunoreactivity 
(Fig. 7A; HR = 1.10, P =. 0068). The presence of epithelioid cells predicted 0.25 higher 10-year 
melanoma-specific mortality (0.30 for spindle cells, 0.55 for epithelioid cells) after its effect was 
adjusted for LBD, microvascular loops and networks, MVD, and ezrin immunoreactivity (Fig 7B; HR 
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= 2.25, P =. 0025). Tumors with loops or networks tended to have a higher 10-year melanoma-specific 
mortality than patients without loops (0.34 for absence of loops, 0.49 for presence of loops, 0.44 for 
presence of networks) after adjustment with LBD, cell type, MVD, ezrin immunoreactivity (Fig. 7C; 
HR = 1.30, P = .10). Notably, melanomas with loops only and those with networks did not differ from 
each other in survival after adjustment. High microvascular density indicated increased 10-year 
melanoma-specific mortality (0.21 for MVD ≤ 24, 0.34 for MVD 25-40, 0.47 for MVD 41-57, and 
0.51 for MVD 2) after adjustment with LBD, cell type, and microvascular loops 
and networks, and ezrin immunoreactivity (Fig. 7D; HR = 1.18, P = .031). Ezrin immunopositive 
tumors tended to have a higher 10-year melanoma-specific mortality than ezrin immunonegative 
tumors (0.29 for ezrin immunonegative, 0.45 for ezrin immunopositive) after adjustment with LBD, 
cell type, microvascular loops and networks, and MVD (Fig. 7E; HR = 1.70, P = .093). The adjusted 
melanoma-specific mortality was 0.28 unit higher among patients with many macrophages than in 
patients with few macrophages (Fig. 7F; HR not available for macrophages). 
 
The adjusted survival analysis indicated that LBD, cell type, and MVD have independent prognostic 
significance in the present, consecutive and unselected series of uveal melanoma patients. The adjusted 
survival curves allow estimation of the size of effect for each variable independently taking into 
account other variables. Cox regression analysis may also be applied to generate survival curves for an 
individual patient,254 but 95% confidence intervals for such curves can not be calculated by 
conventional statistic programs.  
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Figure 7. The covariate-adjusted melanoma-specific survival curves generated by Cox regression 
analysis without stratification of macrophages (A-E). Adjusted survival curves separated for LBD (A), 
Cell type (B), Microvascular loops and networks (C), MVD (D), and Ezrin immunoreactivity (E). Cox 
regression analysis (Table 9) stratified by the Number of macrophages (F).  
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6. SUMMARY AND CONCLUSIONS 
 
Malignant melanoma of the uvea is a rare malignancy that has a well-documented capacity to 
metastasize hematogenously and to kill the patient.11 Although the mortality of uveal melanoma has 
remained fairly constant for decades, the natural history of choroidal and ciliary body melanomas is not 
fully understood.93,95 Important clinical prognostic factors for death from uveal melanoma are the size 
of the tumor, the location of tumor, and extrascleral tumor extension.97,255 The onset of metastatic 
disease is an unfortunate occurrence and the patient’s life expectancy is then only several months to a 
few years.29,30 However, a significant portion of patients with uveal melanoma may survive even 
decades without evidence of metastasis. This clinicopathologic study was undertaken to improve 
understanding of factors that are associated with the development of uveal melanoma metastasis and 
which have an adverse effect on the clinical course of the disease. Factors related to tumor stroma 
(microvascular patterns and MVD), host response (macrophages), and tumor cells (ezrin) were 
investigated.   
 
Most researchers wish that the results of their analyses could be generalized as widely as possible. A 
basic rule in the study design and generalizing statistical results is that the sample must represent the 
true underlying population. This is best ensured by enrolling consecutive and population based samples 
as in the current study, and if not possible, by random sampling. With minimal loss of follow-up data, 
the outcome of 167 Finnish patients with uveal melanoma showed that metastasis was their leading 
cause of death even 15 to 20 years after the removal of the eye. Because this series is exceptionally 
well documented, causes of death are well ascertained, and the inclusion rate is higher than in vast 
majority of studies, there is a reason to believe that, in spite of the relatively small number of tumors, 
the results should be well representative of the entire population of patients with uveal melanoma. In 
this regard, the present study compares favorably with many much larger series based on tertiary 
referral centre populations and cancer registry data.     
 
Microcirculation is a prerequisite for tumor growth and metastasis.256 Tumor vessels differ from 
vessels in nonneoplastic tissue; they are actively proliferating and remodelling.158 The knowledge of 
the prognostic significance of microvascular factors has rapidly increased also in uveal 
melanoma.102,104,105,141,144,147,152 The presence of specific microvascular patterns, 104,141,144,147,152 as well 
as high MVD have been associated with survival of uveal melanoma,105 but controversies regarding 
their relation and even their existence and genesis have been prominent.148,157,165 This controversy is 
about to stimulate research in many areas of tumor biology and several types of cancer. The current 
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study confirmed the relationship between presence of microvascular loops and networks and high 
melanoma-specific mortality. Using multivariate analysis, however, another microvessel parameter, 
MVD, showed independent prognostic significance in addition to loops and networks. In univariate 
analysis, high MVD was associated with presence of microvascular loops and networks, but their 
closer interrelationship remained unsolved and must be addressed on a qualitative level in future 
studies to find out what microvascular patterns are associated with “hot spots” of high MVD. Both 
MVD and microvascular patterns were associated with nonspindle cell type, which might suggest an 
interplay with an aggressive cell type and microvessels. 
 
In addition to microvessels, tumor-infiltrating immune cells, such as macrophages and lymphocytes 
constitute a prominent stromal component within tumors.110,257 The infiltration of macrophages has, 
however, been underreported in uveal melanoma: little attention has been paid on the function of 
macrophages and their potential clinical implications. The present study indicated that the infiltration 
of macrophages varies from low to high between uveal melanomas. Moreover, two morphological 
types, round and dendritic, of tumor-infiltrating macrophages were identified. The dense infiltration of 
macrophages was associated with decreased survival and high MVD, suggesting an active role in 
modulation of microvessels. The morphological type of macrophages did not show any prognostic 
significance. Tumor-infiltrating macrophages must also be remembered as a source of cross-
reactivity.112,172,175 They have been recently shown to express epidermal growth factor receptor and a 
cytoplasmic form of estrogen receptor in uveal melanoma, initially thought to reside in tumor 
cells.112,175 
 
Uveal melanoma cells immunoreactive with mAb to ezrin, the ultimate function of which in tumors is 
unknown, were more often present in tumors that metastasized rapidly than in tumors that did not 
metastasize or metastasized later. The immunoreactivity of ezrin retained a borderline independent 
prognostic significance in multivariate analysis after adjusting for the presence of microvascular loops 
and networks, MVD, the presence of epithelioid cells, and LBD. The immunoreactivity of ezrin was 
associated with MVD and high numbers of tumor-infiltrating macrophages. This study is not able to 
answer, whether any biological relationship exists between MVD, ezrin, and macrophages, and an 
experimental approach will be needed. Macrophages are multifunctional cells that secrete e.g. HGF 
that modulates microvessels, and ezrin is a downstream target of HGF.250,251,258 Further studies, in 
particular experimental ones, are needed to investigate the tumor biology of uveal melanoma. Host 
factors in particular have not been studied enough, and why an occasional patient with uveal melanoma 
of high-risk features may survive for a long time, remains a mystery.  
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